<?xml version="1.0" encoding="iso-8859-1"?>
		<rss version="2.0" >
        <channel>
        <title>rellease ID</title>
        <link>https://relleaseid.com/</link>
        <description>situs relleaseID</description>
        <language>en-us</language>
        <pubDate>Tue, 03 Nov 2026 22:30:32 +0700</pubDate>
        <lastBuildDate>Tue, 03 Nov 2026 22:30:32 +0700</lastBuildDate>
        <generator>rellease ID RSS Generator</generator>
        <managingEditor>relleaseid@gmail.com</managingEditor>
        <webMaster>arie.vcr@gmail.com</webMaster>
		<image>
		<url>https://relleaseid.com/icon.gif</url>
		<title>rellease ID</title>
		<link>https://relleaseid.com/</link>
		<description>Fasilitas RSS dari relleaseID</description>
		</image>
<item>
<title>Seyond Expands Smart City Solution with LiDAR-Powered Operational Twin Capabilities and Technology Collaborations</title>
<link>https://relleaseid.com/berita-bisnis/Seyond-Expands-Smart-City-Solution-with-LiDAR-Powered-Operational-Twin-Capabilities-and-Technology-Collaborations</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/4720_Seyond-Expands-Smart-City-Solution-with-LiDAR-Powered-Operational-Twin-Capabilities-and-Technology-Collaborations.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.</div><div><br></div><div>SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations. </div><div><br></div><div>By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.</div><div><br></div><div>Growing Demand for Smart Cities and Intelligent Infrastructure</div><div><br></div><div>Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.</div><div><br></div><div>Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.</div><div><br></div><div>Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.</div><div><br></div><div>Seyond: Enabling Spatial Intelligence Across Smart Environments</div><div><br></div><div>Seyond&#039;s comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.</div><div><br></div><div>These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond&#039;s sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.</div><div><br></div><div>Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions</div><div><br></div><div>Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.</div><div><br></div><div>At Smart City Expo World Congress 2026, November 3-5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.</div><div><br></div><div>By combining Seyond&#039;s sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU.</div><div><br></div><div> Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.</div><div><br></div><div>Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond&#039;s LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.</div><div><br></div><div>In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.</div><div><br></div><div>Together, these collaborations demonstrate Seyond&#039;s expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.</div><div><br></div><div>About Seyond</div><div><br></div><div>Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 22:22:00 +0700</pubDate>
</item>
<item>
<title>Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions</title>
<link>https://relleaseid.com/berita-bisnis/Hopscotch-launches-Hopscotch-Public-Engagement--a-new-entity-dedicated-to-the-European-institutions</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/9172_Hopscotch-launches-Hopscotch-Public-Engagement--a-new-entity-dedicated-to-the-European-institutions.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Press release</div><div>Paris, November 3rd 2026 --</div><div><br></div><div>Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions</div><div><br></div><div>The communications Group is combining its integrated expertise and international network to support the EU institutions meet their communication challenges and the demands of major public contracts.</div><div><br></div><div>HOPSCOTCH, the international communications Group founded in France, today announces the launch of Hopscotch Public Engagement. The new Brussels-based entity will primarily serve the EU institutions and, more broadly, the European public sector.</div><div><br></div><div>The launch reflects the Group&#039;s ambition to strengthen its presence with the EU institutions. Much of their communication work is commissioned through multi-year framework contracts spanning several areas of expertise and several countries. Hopscotch Public Engagement will meet these needs by drawing on the strengths of an integrated communications group: specialist expertise, sector knowledge and the ability to deliver across Europe.</div><div><br></div><div>An integrated offer built for the challenges of public communication</div><div><br></div><div>From 360? communication campaigns to events, digital, influence and public relations, Hopscotch Public Engagement brings together the Group&#039;s expertise to design and deliver communication strategies suited to the complexity of EU issues. This integrated approach meets the wide range of the institutions&#039;needs. It is also built for framework contracts, which are typically split into multiple lots and require several disciplines and teams to work in close coordination.</div><div><br></div><div>The entity builds on the experience HOPSCOTCH has developed with private- and public-sector clients, adapting it to the conventions and requirements of EU institutional communication. This includes the Group&#039;s approaches to Relational Capital and augmented public relations, which help institutions explain their work, strengthen dialogue with their audiences and deliver their messages at the right time.</div><div><br></div><div>The offer relies on the Group&#039;s sector expertise and international network. As an independent European group, HOPSCOTCH has more than 40 offices worldwide. Its organisation is designed to support pan-European campaigns and to coordinate communication programmes across European markets.</div><div><br></div><div>The Group also draws on the experience of its international network, formerly Sopexa, in supporting regulated sectors and European programmes for agriculture and food industry players. It also runs international campaigns on behalf of the European Commission&#039;s Directorate-General for Agriculture and Rural Development (DG AGRI) and the European Research Executive Agency (REA).</div><div><br></div><div>"The launch of Hopscotch Public Engagement reflects a conviction the Group holds firmly: the biggest communication challenges now play out at European level. With this new entity, we are combining in-depth knowledge of the institutions with our network&#039;s ability to coordinate programmes across European and international markets," says Sylvain Rouchy, Vice President, Global Operations at HOPSCOTCH.</div><div><br></div><div>Based in Brussels, Hopscotch Public Engagement works alongside Hopscotch Belgium, the Group&#039;s brand communication agency for the Belgian market, led by M?lanie Rouchy.</div><div><br></div><div>"Setting up Hopscotch Public Engagement in Brussels is a great opportunity to strengthen synergies within the Group and to put our complementary expertise at the service of the European institutions," says M?lanie Rouchy, Managing Director of Hopscotch Belgium.</div><div><br></div><div>A shared ambition to serve Europe</div><div><br></div><div>Hopscotch Public Engagement is co-led by Caroline Danloy and Nicolas Balland. Between them, they bring knowledge of the European institutions, communications expertise and experience in leading multidisciplinary teams.</div><div><br></div><div>Caroline Danloy has extensive experience in strategic communication for international and European institutional clients. Over a 25-year career, she has served as Vice President at ICF Next, where she led 360? communication teams delivering major European campaigns.</div><div><br></div><div>"We are at a turning point for European democracy. Communicating about the work of the European institutions and the challenges they face is more important than ever, and it is a mission I have been proud to carry out for 25 years," says Caroline Danloy, Co-Managing Director of Hopscotch Public Engagement.</div><div><br></div><div>"Hopscotch brings a rare combination to this market: the scale and maturity of an international network headquartered in France, expertise spanning the public and private sectors, and real depth of subject knowledge. Communicating for public institutions involves many topics and stakeholders, and this combination is exactly what that complexity demands. Alongside Nicolas, whose experience I know well, I look forward to putting these strengths at the service of the European institutions with Hopscotch Public Engagement."</div><div><br></div><div>Nicolas Balland brings more than 20 years of experience in the communications industry, particularly in events, public relations and institutional communication. After holding various roles at ICF Next, he joined Tipik, where he led Event, Studio and Audiovisual teams before becoming Managing Director.</div><div><br></div><div>"This is a project Caroline and I had been thinking about for several years. When we met Hopscotch, we quickly realised that we shared the same ambition," explains Nicolas Balland, Co-Managing Director of Hopscotch Public Engagement.</div><div><br></div><div>"Today, we are proud to offer the European institutions the strength of a leading communications Group, combined with distinctive expertise and in-depth knowledge of European issues. Our ambition goes beyond designing and delivering communication campaigns: we want to build an organisation that connects institutions, citizens and ideas, and that takes concrete action for Europe."</div><div><br></div><div>--</div><div>About HOPSCOTCH&nbsp;&nbsp;</div><div><br></div><div>HOPSCOTCH is an international communications Group founded in France, driven by an entrepreneurial vision and the complementary nature of its talents and expertise.&nbsp;</div><div>HOPSCOTCH is a unique combination of expertise, driven by the belief that the value of a company or organisation lies in the quality of its Relational Capital.&nbsp;</div><div>With more than 1,200 employees, half of whom are based internationally (40 offices across 5 continents), HOPSCOTCH covers all areas of communication: influence, events, public relations, activations, digital, internal communication, public affairs, and marketing services.&nbsp;</div><div>HOPSCOTCH organises its agencies around its areas of expertise:&nbsp;</div><div>Event: Hopscotch Event, Hopscotch Congr?s, Hopscotch Moments, Sagarmatha.&nbsp;</div><div>Public Relations: Hopscotch PR, Le Public Syst?me PR, Human to Human, Hopscotch D?cideurs.&nbsp;&nbsp;</div><div>Digital and Marketing: heaven, AD Crew, Hopscotch Digital Studio, Sublime.&nbsp;</div><div>Media: Hopscotch Media&nbsp;</div><div>Sectorial expertise: Hopscotch Cin?ma, Hopscotch Luxe, Hopscotch Season, Hopscotch Sport, Hopscotch Tourism.&nbsp;</div><div>HOPSCOTCH has been committed to ambitious ecological and societal initiatives for over 15 years, validated by internationally recognized CSR certifications, including RSE Agences Actives, ISO 20121, and the EcoVadis Gold medal.&nbsp;</div><div><br></div><div>In 2026, HOPSCOTCH was named "Global Agency of the Year" by PRovoke Media.&nbsp;</div><div>Listed on Euronext Growth Paris (Ticker code: ALHOP FR ; ISIN code: FR 00000 6527 8), the Group represents a turnover of ?270,8 million and a gross margin of ?98,8 million in 2025.&nbsp;&nbsp;</div><div>Follow us: www.hopscotch.one and on LinkedIn / X / Instagram / Bluesky @HOPSCOTCHGroupe&nbsp;</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 22:19:00 +0700</pubDate>
</item>
<item>
<title>Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.</title>
<link>https://relleaseid.com/berita-bisnis/Teva-and-Samsung-Bioepis-Announce-Agreement-to-Commercialize-Two-FDA-Approved-Biosimilars-in-the-U-S-</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/6377_.jpg border=0 hspace=5 align=left width=350 /><ul>*Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO upon close and infliximab-abda in Q3 2027</ul><ul>*Collaboration combines Samsung Bioepis&#039; biosimilar expertise with Teva&#039;s commercial capabilities</ul><ul>*Agreement expands collaboration with Samsung Bioepis, strengthening Teva&#039;s generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy</ul><ul>TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that they have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade 1 (infliximab) and ETICOVO (etanercept-ykro), a biosimilar to Enbrel 2 (etanercept).</ul><ul>Under the terms of the agreement, Teva will obtain U.S. commercialization rights to etanercept-ykro at closing, while U.S. commercialization rights to infliximab-abda will transfer to Teva in Q3 2027. The timing of Teva&#039;s future U.S. commercialization of etanercept-ykro will be announced at a later date. Samsung Bioepis will remain responsible for regulatory oversight and manufacturing of both products. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the end of 2026.</ul><ul>"This agreement strengthens our collaboration with Samsung Bioepis and will expand our U.S. immunology portfolio with two additional biologic treatment options," said Richard Francis, President and CEO of Teva. "Biosimilars are an important part of our Pivot to Growth strategy, helping us build a stronger portfolio while expanding access to high-quality medicines. Together, we have an opportunity to bring more treatment choices to patients living with chronic inflammatory conditions."</ul><ul>"We are delighted to expand our strategic alliance with Teva to strengthen the commercial footprint of our immunology portfolio in the U.S.," said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. "Infliximab-abda has established a proven track record of clinical efficacy and supply reliability since its launch, while ETICOVO represents an FDA-approved therapy poised to broaden treatment choices for patients. By pairing our dedication to high-quality biologic development and manufacturing with Teva&#039;s commercial reach across U.S. healthcare channels, we aim to ensure uninterrupted treatment continuity for existing patients and bring sustainable value to the U.S. healthcare system."</ul><ul>Under the terms of the agreement and subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment over the next 3 years. Samsung Bioepis may be eligible for additional launch and sales milestones payments. Teva and Samsung Bioepis will share profit from the commercialization of these products.</ul><ul>The agreement builds on a series of biosimilar collaborations between Teva and Samsung Bioepis. In 2025, the companies announced a U.S. agreement for EPYSQLI (eculizumab-aagh), a biosimilar to Soliris3 (eculizumab). In 2026, the companies announced two agreements, including one for OPUVIZ (aflibercept) in Canada and a separate global agreement to license, develop and commercialize up to six potential biosimilar candidates currently in early-stage development, including biosimilar candidates referencing Fasenra4 (benralizumab) and Ilaris5 (canakinumab).</ul><ul>About Infliximab-abda and etanercept-ykro</ul><ul>Both biosimilars are tumor necrosis factor (TNF) inhibitors indicated for the treatment of chronic inflammatory and autoimmune conditions:</ul><ul>infliximab-abda6 was approved by the FDA in 2017 for indications including Crohn&#039;s disease (adult and pediatric), ulcerative colitis (adult and pediatric), rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Teva will newly assume commercialization of the product, scheduled to take effect in the third quarter of 2027.</ul><ul>etanercept-ykro7 was approved by the FDA in 2019 and is not currently available on the U.S. market. It is approved for indications including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (patients aged 2 years and older), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis (patients aged 4 years and older).</ul><ul>IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR INFLIXIMAB-ABDA</ul><ul>SERIOUS INFECTIONS</ul><ul>Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue infliximab-abda if a patient develops a serious infection or sepsis.</ul><ul>Reported infections include:</ul><ul>Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab-abda use and during therapy. Treatment for latent infection should be initiated prior to infliximab-abda use.</ul><ul>Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis, and cryptococcosis. Patients may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.</ul><ul>Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella, Listeria, and Salmonella.</ul><ul>The risks and benefits of treatment with infliximab-abda should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with infliximab-abda, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.</ul><ul>Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab products included pneumonia, cellulitis, abscess, and skin ulceration.</ul><ul>MALIGNANCIES</ul><ul>Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin&#039;s and non-Hodgkin&#039;s lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.</ul><ul>Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn&#039;s disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with infliximab-abda, especially in these patient types.</ul><ul>In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn&#039;s disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF inhibitors, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with infliximab products was similar to that expected in the general population whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF inhibitors in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).</ul><ul>Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.</ul><ul>A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-na?ve patients or the general population, particularly those over 60 years of age. A causal relationship between infliximab products and cervical cancer cannot be excluded. Periodic screening should continue in women treated with infliximab products.</ul><ul>CONTRAINDICATIONS</ul><ul>The use of infliximab-abda at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. infliximab-abda is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab products or any of the inactive ingredients of infliximab-abda or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).</ul><ul>WARNINGS AND PRECAUTIONS</ul><ul>HEPATITIS B REACTIVATION</ul><ul>TNF inhibitors, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating INFLIXIMAB-ABDA. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing infliximab-abda for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with INFLIXIMAB-ABDA. Discontinue infliximab-abda in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of infliximab-abda and monitor patients closely.</ul><ul>HEPATOTOXICITY</ul><ul>Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported rarely in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, &#8805;5 times the upper limit of normal) develop, infliximab-abda should be discontinued, and a thorough investigation of the abnormality should be undertaken.</ul><ul>HEMATOLOGIC EVENTS</ul><ul>Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported in patients using infliximab products. The causal relationship to infliximab therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of infliximab-abda in patients who develop significant hematologic abnormalities.</ul><ul>HYPERSENSITIVITY</ul><ul>Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset and required hospitalization in some cases. Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension) have occurred during or within 2 hours of infliximab product infusion. Serious infusion reactions including anaphylaxis were infrequent. infliximab-abda should be discontinued for severe hypersensitivity reactions. Medications for the treatment of hypersensitivity reactions should be available.</ul><ul>CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION</ul><ul>Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of infliximab infusion. Cases of transient visual loss have been reported during or within 2 hours of infusion of infliximab. Monitor patients during infusion and, if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.</ul><ul>NEUROLOGIC EVENTS</ul><ul>TNF inhibitors, including infliximab products, have been associated in rare cases with central nervous system (CNS) manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr? syndrome. Exercise caution when considering infliximab-abda in patients with these disorders and consider discontinuation if these disorders develop.</ul><ul>AUTOIMMUNITY</ul><ul>Treatment with infliximab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.</ul><ul>DRUG INTERACTIONS</ul><ul>USE WITH OTHER DRUGS</ul><ul>Concurrent use of infliximab-abda with other biological products used to treat the same conditions as infliximab-abda is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.</ul><ul>VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS</ul><ul>Prior to initiating infliximab-abda in pediatric and adult patients, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with infliximab-abda due to the possibility of clinical infections, including disseminated infections.</ul><ul>At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products.</ul><ul>ADVERSE REACTIONS</ul><ul>In clinical trials, the most common adverse reactions occurring in >10% of patients included infections (e.g., upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.</ul><ul>INDICATIONS</ul><ul>Infliximab-abda is a TNF blocker indicated for:?</ul><ul>Crohn&#039;s Disease</ul><ul>Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn&#039;s disease (CD) who have had an inadequate response to conventional therapy.</ul><ul>Infliximab-abda is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn&#039;s disease.</ul><ul>Pediatric Crohn&#039;s Disease</ul><ul>Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn&#039;s disease (CD) who have had an inadequate response to conventional therapy.</ul><ul>Ulcerative Colitis</ul><ul>Infliximab-abda is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.</ul><ul>Pediatric Ulcerative Colitis</ul><ul>Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.</ul><ul>Rheumatoid Arthritis</ul><ul>Infliximab-abda is indicated, in combination with methotrexate (MTX), for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).</ul><ul>Ankylosing Spondylitis</ul><ul>Infliximab-abda is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).</ul><ul>Psoriatic Arthritis</ul><ul>Infliximab-abda is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).</ul><ul>Plaque Psoriasis</ul><ul>Infliximab-abda is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Infliximab-abda should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.</ul><ul>Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.</ul><ul>IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR ETICOVO (etanercept-ykro)</ul><ul>SERIOUS INFECTIONS</ul><ul><p>Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ETICOVO should not be initiated in the presence of sepsis, active infections, or allergy to ETICOVO or its components. ETICOVO should be discontinued if a patient develops a serious infection or sepsis.</p><p> Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before ETICOVO use and periodically during therapy. Initiate treatment for latent infection prior to ETICOVO use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.</p></ul><ul>The risks and benefits of treatment with ETICOVO should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with ETICOVO, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.</ul><ul>MALIGNANCIES</ul><ul>Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept products.</ul><ul>In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.</ul><ul>Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.</ul><ul>Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including etanercept products. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.</ul><ul>Pediatric Patients</ul><ul>In patients who initiated therapy at &#8804;18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin&#039;s and non-Hodgkin&#039;s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.</ul><ul>CONTRAINDICATIONS</ul><ul>ETICOVO is contraindicated in patients with sepsis.</ul><ul>WARNINGS AND PRECAUTIONS</ul><ul>NEUROLOGIC REACTIONS</ul><ul>Treatment with TNF-blocking agents, including etanercept products, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barr? syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ETICOVO therapy. Prescribers should exercise caution in considering the use of ETICOVO in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.</ul><ul>NEW ONSET OR WORSENING OF HEART FAILURE</ul><ul>Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking etanercept products. Caution should be used when using ETICOVO in patients with CHF. These patients should be carefully monitored.</ul><ul>HEMATOLOGIC REACTIONS</ul><ul>Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to etanercept products therapy remains unclear. Exercise caution when considering ETICOVO in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ETICOVO if significant hematologic abnormalities are confirmed.</ul><ul>HEPATITIS B REACTIVATION</ul><ul>Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including etanercept products. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ETICOVO in these patients.</ul><ul>ALLERGIC REACTIONS</ul><ul>Allergic reactions associated with administration of ETICOVO during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, discontinue administration of ETICOVO and initiate appropriate therapy immediately.</ul><ul>IMMUNIZATIONS</ul><ul>Avoid concurrent administration of live vaccines with ETICOVO. Patients, if possible, should be brought up to date with all immunizations prior to initiating ETICOVO. In patients with exposure to varicella virus, temporarily discontinue ETICOVO and consider prophylactic treatment with Varicella Zoster Immune Globulin.</ul><ul>AUTOIMMUNITY</ul><ul>Autoantibodies may develop with ETICOVO, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ETICOVO. Stop ETICOVO if findings suggestive of lupus-like syndrome or autoimmune hepatitis develop and evaluate the patient.</ul><ul>NOT RECOMMENDED FOR GRANULOMATOSIS WITH POLYANGIITIS PATIENTS ON IMMUNOSUPPRESSANTS</ul><ul>The use of ETICOVO in patients with granulomatosis with polyangiitis receiving immunosuppressive agents (e.g., cyclophosphamide) is not recommended.</ul><ul>INCREASED MORTALITY IN PATIENTS WITH MODERATE TO SEVERE ALCOHOLIC HEPATITIS</ul><ul>Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ETICOVO in patients with moderate to severe alcoholic hepatitis.</ul><ul>DRUG INTERACTIONS</ul><ul>The use of ETICOVO in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ETICOVO and anakinra is not recommended. Hypoglycemia has been reported following initiation of ETICOVO therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</ul><ul>ADVERSE REACTIONS</ul><ul>The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.</ul><ul>In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.</ul><ul>INDICATIONS</ul><ul>ETICOVO (etanercept-ykro) is a TNF blocker indicated for:?</ul><ul>Rheumatoid Arthritis: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).</ul><ul>Polyarticular Juvenile Idiopathic Arthritis (pJIA): Reducing signs and symptoms of moderately to severely active pJIA in patients 2 years of age and older.?</ul><ul>Psoriatic Arthritis: Reducing signs and symptoms, inhibiting structural damage progression, and improving physical function in adults (alone or with methotrexate).?</ul><ul>Ankylosing Spondylitis: Reducing signs and symptoms in patients with active disease.?</ul><ul>Plaque Psoriasis: Treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.</ul><ul>Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.</ul><ul>About Teva</ul><ul>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva&#039;s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients&#039; needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.</ul><ul>Teva Cautionary Note Regarding Forward-Looking Statements</ul><ul>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#039;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the agreement with Samsung Bioepis and to successfully commercialize infliximab-abda and ETICOVO (etanercept-ykro) in the U.S.; our ability to successfully execute our additional collaborations with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Reports on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.</ul><ul>About Samsung Bioepis Co., Ltd.</ul><ul>Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world&#039;s leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.</ul><ul>_______________</ul><ul>1 Remicade is a trademark of Janssen Biotech, Inc., a Johnson & Johnson company</ul><ul>2 Enbrel is a trademark of Immunex Corporation, an Amgen subsidiary.</ul><ul>3 Soliris is a trademark of Alexion Pharmaceuticals, Inc.</ul><ul>4 Fasenra is a trademark of AstraZeneca AB.</ul><ul>5 Ilaris is a trademark of Novartis AG.</ul><ul>6 infliximab-abda - FDA-approved biosimilar to Remicade (infliximab): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761054</ul><ul>7 etanercept-ykro - FDA-approved biosimilar to Enbrel (etanercept): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761066</ul><ul>Copyright 2026 GlobeNewswire, Inc.</ul><ul><li>  </li></ul>   ]]></description>
<pubDate>Tue, 03 Nov 2026 21:54:00 +0700</pubDate>
</item>
<item>
<title>Bridge Data Centres Appoints New Co-Chief Executive Officer</title>
<link>https://relleaseid.com/berita-bisnis/Bridge-Data-Centres-Appoints-New-Co-Chief-Executive-Officer</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/4140_Bridge-Data-Centres-Appoints-New-Co-Chief-Executive-Officer.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Source: Bridge Data Centres</div><div><br></div><div>Mr Drew Chen&#039;s appointment as Co-CEO strengthens BDC&#039;s leadership team as the Company surpasses one gigawatt of capacity in 2026 and accelerates its growth across Asia Pacific.</div><div><br></div><div>SINGAPORE - Media OutReach Newswire - 3 November 2026 - Bridge Data Centres (BDC) is pleased to announce the appointment of Mr Drew Chen as Co-Chief Executive Officer (Co-CEO), effective 1 November 2026. He will work alongside Mr Eric Fan, BDC&#039;s Co-CEO, as a key member of the leadership team to accelerate the Company&#039;s growth across Asia Pacific and beyond.</div><div><br></div><div>Mr Chen brings over 20 years of private equity experience, with a focus on the telecommunications, media, technology, and business services sectors. He previously served as a Senior Partner at Bain Capital and was a founding member of the firm&#039;s Asia Pacific private equity team. </div><div><br></div><div>Prior to Bain Capital, Mr Chen worked at Bain & Company. He holds a bachelor&#039;s degree in economics from Harvard University and an MBA from Harvard Business School.</div><div><br></div><div>Mr Eric Fan, Co-CEO of Bridge Data Centres, said, "On behalf of Bridge Data Centres, we would like to welcome Drew. His appointment strengthens our leadership team at an important point in BDC&#039;s growth, as we surpass one gigawatt of capacity in 2026. Drew&#039;s experience and deep domain knowledge of the data centre sector will support our strategy as we scale BDC into a multi-gigawatt digital infrastructure platform in the coming years."</div><div><br></div><div>Mr Drew Chen, Co-CEO of Bridge Data Centres, said, "The Asia Pacific data centre sector is at inflection point for growth, fuelled by surging cloud adoption and the rapid expansion of AI workloads. BDC is well positioned to capture this opportunity, backed by our world class engineering and design team, longstanding partnerships with global clients, and a decade of experience developing and operating next-generation digital infrastructure. I am excited to partner with Eric and the leadership team to scale BDC&#039;s footprint across Asia Pacific and support our customers&#039; ambitious growth plans."</div><div><br></div><div>Mr Jonathan Zhu, Partner and Chair of China at Bain Capital, said, "Drew possesses deep expertise in the digital infrastructure space and an intimate knowledge of BDC&#039;s business, having played a pivotal role in the buildout of BDC and its sister company ChinData. We are delighted that, as the Co-CEO, Drew will continue to bring strategic foresight and robust business building capabilities to BDC. Together, he and Eric are well positioned to lead BDC through its next chapter of growth."</div><div><br></div><div>Headquartered in Singapore, BDC is one of Asia Pacific&#039;s top three next-generation digital infrastructure platforms by live capacity, with a presence across Malaysia, Thailand, Singapore, and India.</div><div><br></div><div>About Bridge Data Centres</div><div>Bridge Data Centres (BDC) is a Singapore headquartered digital infrastructure platform delivering next-generation data centres across Asia Pacific and beyond.</div><div><br></div><div>Backed by Bain Capital, BDC operates in Malaysia, Thailand, India, and other high-growth markets, with an ambition to scale into a multi-gigawatt digital infrastructure platform in the near future.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Hashtags: #BridgeDataCentres</div><div><br></div><div>https://www.bridgedatacentres.com/</div><div>https://th.linkedin.com/company/bridgedc</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 21:44:00 +0700</pubDate>
</item>
<item>
<title>YYForce Menyoroti Aset Bersih yang Dilaporkan Sebesar US$21,9 Juta serta Menguraikan Prioritas Robotika Komersial dan Platform AI</title>
<link>https://relleaseid.com/berita-bisnis/YYForce-Menyoroti-Aset-Bersih-yang-Dilaporkan-Sebesar-US-21-9-Juta-serta-Menguraikan-Prioritas-Robotika-Komersial-dan-Platform-AI</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/5529_YYForce-Menyoroti-Aset-Bersih-yang-Dilaporkan-Sebesar-US-21-9-Juta-serta-Menguraikan-Prioritas-Robotika-Komersial-dan-Platform-AI.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>YYForce menyajikan nilai buku ekuitas yang telah dilaporkan beserta kapitalisasi pasarnya untuk memberikan konteks tambahan terkait rencana pertumbuhan perusahaan kepada rencana pertumbuhan perusahaan</div><div><br></div><div>SINGAPURA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- YYForce Inc. (Nasdaq: YFOR) ("YYForce" atau "Perusahaan"), penyedia solusi tenaga kerja dan layanan pengelolaan fasilitas terpadu berbasis teknologi, hari ini menyoroti aset bersih perusahaan yang dilaporkan sebesar sekitar US$21,9 juta, dibandingkan dengan estimasi kapitalisasi pasar sekitar US$2,1 juta per 30 Oktober 2026, serta menguraikan prioritas perusahaan di bidang robotika komersial dan AI.</div><div><br></div><div>YYForce menyampaikan informasi ini untuk membantu investor mengevaluasi basis aset yang dilaporkan perusahaan beserta hasil operasional, likuiditas, serta strateginya di bidang platform tenaga kerja, pengelolaan fasilitas terpadu, dan robotika layanan.</div><div><br></div><div>Posisi keuangan yang dilaporkan dan perbandingan valuasi</div><div><br></div><div>Sebagaimana dilaporkan dalam Formulir 6-K Perusahaan yang telah disampaikan pada 25 September 2026, neraca konsolidasian YYForce per 30 Juni 2026 menunjukkan angka-angka berikut.</div><div><br></div><div><table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0">
 <tbody><tr>
  <td valign="top" style="border:solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal"><b><span style="font-size:12.0pt;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman"">Pos neraca</span></b><span style="font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:
  "Times New Roman""><o:p></o:p></span></p>
  </td>
  <td valign="top" style="border:solid black 1.0pt;border-left:none;mso-border-left-alt:
  solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal"><b><span style="font-size:12.0pt;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman"">Jumlah yang dilaporkan</span></b><span style="font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:
  "Times New Roman""><o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td valign="top" style="border:solid black 1.0pt;border-top:none;mso-border-top-alt:
  solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman"">Total aset<o:p></o:p></span></p>
  </td>
  <td valign="top" style="border-top:none;border-left:none;border-bottom:solid black 1.0pt;
  border-right:solid black 1.0pt;mso-border-top-alt:solid black 1.0pt;
  mso-border-left-alt:solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman"">Sekitar US$38 juta<o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td valign="top" style="border:solid black 1.0pt;border-top:none;mso-border-top-alt:
  solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman"">Ekuitas yang dapat diatribusikan
  kepada pemegang saham YYForce (aset bersih)<o:p></o:p></span></p>
  </td>
  <td valign="top" style="border-top:none;border-left:none;border-bottom:solid black 1.0pt;
  border-right:solid black 1.0pt;mso-border-top-alt:solid black 1.0pt;
  mso-border-left-alt:solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman"">Sekitar US$21,9 juta<o:p></o:p></span></p>
  </td>
 </tr>
</tbody></table>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p></div><div>Per 30 Oktober 2026, estimasi kapitalisasi pasar ekuitas perusahaan mencapai sekitar US$2,1 juta, setara dengan sekitar 9,6% dari ekuitas yang dilaporkan dan dapat diatribusikan kepada pemegang saham YYForce. Angka tersebut menunjukkan diskon sekitar 90,4% terhadap nilai buku ekuitas yang dilaporkan. Informasi ini menggunakan angka yang telah dibulatkan serta mencerminkan data keuangan dan data pasar dari tanggal yang berbeda.</div><div><br></div><div>Nilai buku ekuitas tidak mencerminkan kas yang penggunaannya tidak dibatasi, aset bersih berwujud, hasil likuidasi, atau estimasi nilai intrinsik. Nilai tercatat aset bergantung pada estimasi akuntansi dan penilaian penurunan nilai. Investor perlu mempertimbangkan laporan keuangan secara keseluruhan, termasuk liabilitas, hasil operasional, arus kas, dan pengungkapan selanjutnya.</div><div><br></div><div>Komentar manajemen</div><div><br></div><div>"Kami meyakini bahwa selisih antara nilai buku ekuitas yang kami laporkan dan kapitalisasi pasar perusahaan di pasar publik patut mendapat perhatian investor," ujar Mike Fu, Chief Executive Officer YYForce. "Tanggung jawab kami adalah menyediakan informasi keuangan yang jelas dan melaksanakan strategi komersial kami. Kami tetap berfokus pada penyediaan layanan bagi pelanggan, alokasi modal yang disiplin, serta pengembangan bisnis solusi tenaga kerja, pengelolaan fasilitas, dan robotika layanan kami."</div><div><br></div><div>"Kami akan mengevaluasi setiap investasi berdasarkan permintaan pelanggan, likuiditas yang tersedia, kebutuhan modal, dan imbal hasil yang diharapkan," tambah Fu.</div><div><br></div><div>Prioritas pertumbuhan strategis</div><div><br></div><div>Ekspansi robotika komersial. Mengupayakan penerapan robotika layanan dan integrasinya ke dalam alur kerja sektor perhotelan dan perusahaan, dengan memperhatikan kebutuhan pelanggan, biaya penerapan, serta dukungan berkelanjutan.</div><div><br></div><div>Platform pengelolaan fasilitas dan tenaga kerja yang didukung AI. Mengembangkan kemampuan platform digital dan mendorong penerapannya di perusahaan untuk mendukung koordinasi tenaga kerja, pelaksanaan shift kerja, dan operasional fasilitas.</div><div><br></div><div>Disiplin pengelolaan modal dan transparansi pasar. Mengevaluasi penerapan komersial berdasarkan permintaan pelanggan, kebutuhan modal, dan imbal hasil yang diharapkan. Selain itu, memberikan informasi terbaru yang jelas kepada pemegang saham mengenai perkembangan yang signifikan.</div><div><br></div><div>YYForce akan terus menilai kinerja operasional, kebutuhan pembiayaan, dan prioritas alokasi modalnya sesuai dengan perkembangan bisnisnya. Kemajuan komersial di masa mendatang tetap bergantung pada pelaksanaan operasional, tingkat adopsi oleh pelanggan, dan kondisi pasar yang lebih luas.</div><div><br></div><div>Tentang YYForce Inc.</div><div><br></div><div>YYForce Inc. (Nasdaq: YFOR) adalah perusahaan penyedia solusi tenaga kerja dan layanan pengelolaan fasilitas terpadu berbasis teknologi. Perusahaan tengah mengembangkan platform pengelolaan tenaga kerja dan kapabilitas robotika berteknologi AI untuk mendukung kegiatan operasional di lini depan, meningkatkan produktivitas, serta memenuhi kebutuhan pelanggan yang terus berkembang.</div><div><br></div><div>Untuk informasi lebih lanjut, kunjungi www.yyforce.ai.</div><div><br></div><div>Pernyataan Berwawasan ke Depan</div><div><br></div><div>Siaran pers ini memuat pernyataan berwawasan ke depan sebagaimana dimaksud dalam Pasal 27A Undang-Undang Sekuritas AS Tahun 1933, sebagaimana telah diubah, dan Pasal 21E Undang-Undang Perdagangan Sekuritas AS Tahun 1934, sebagaimana telah diubah. Pernyataan-pernyataan tersebut didasarkan pada ekspektasi dan asumsi Perusahaan saat ini, serta informasi yang tersedia bagi Perusahaan pada tanggal rilis siaran pers ini. Pernyataan berwawasan ke depan dapat dikenali melalui penggunaan kata-kata seperti "mungkin", "akan", "seharusnya", "memperkirakan", "mengantisipasi", "merencanakan", "bermaksud", "meyakini", "mengestimasi", "potensi", atau ungkapan serupa, maupun bentuk negatif dari istilah-istilah tersebut.</div><div><br></div><div>Pernyataan berwawasan ke depan dalam siaran pers ini termasuk, tetapi tidak terbatas pada, ekspektasi mengenai strategi, penerapan komersial, pengembangan platform, efisiensi operasional, alokasi modal, dan kinerja bisnis Perusahaan di masa mendatang. Data keuangan historis bukan merupakan pernyataan berwawasan ke depan. Nilai buku ekuitas yang dilaporkan bukan merupakan indikator harga yang mungkin berlaku dalam perdagangan saham perusahaan maupun jumlah yang mungkin diperoleh dari penjualan atau likuidasi.</div><div><br></div><div>Pernyataan berwawasan ke depan mengandung risiko dan ketidakpastian yang melekat, dan peristiwa di masa mendatang yang dibahas dalam siaran pers ini mungkin tidak terjadi. Peristiwa dan hasil aktual dapat berbeda secara signifikan serta bergantung pada risiko, ketidakpastian, asumsi mengenai Perusahaan, dan sejumlah faktor lainnya. </div><div><br></div><div>Untuk pembahasan lebih terperinci mengenai faktor-faktor risiko, silakan merujuk pada dokumen yang diserahkan Perusahaan kepada Komisi Sekuritas dan Bursa AS (SEC), termasuk bagian "Faktor Risiko" dalam laporan tahunan terbaru Perusahaan pada Formulir 20-F, sebagaimana diubah. YYForce tidak berkewajiban untuk memperbarui pernyataan ini kecuali sebagaimana diwajibkan oleh hukum yang berlaku.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 21:31:00 +0700</pubDate>
</item>
<item>
<title>Berakar pada Perpetua, EXEED Memperkenalkan Bahasa Desain Barunya: Kemewahan Masa Depan</title>
<link>https://relleaseid.com/berita-bisnis/Berakar-pada-Perpetua--EXEED-Memperkenalkan-Bahasa-Desain-Barunya--Kemewahan-Masa-Depan</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/1927_Berakar-pada-Perpetua--EXEED-Memperkenalkan-Bahasa-Desain-Barunya--Kemewahan-Masa-Depan.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>SHANGHAI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Acara "Peluncuran Bahasa Desain Baru" berlangsung di Pusat Inovasi Teknologi Global Chery di Shanghai sebagai bagian dari EXEED International User Summit 2026. Mengusung tema "Kemewahan Masa Depan", acara tersebut memperkenalkan bahasa desain baru untuk seluruh lini kendaraan EXEED. </div><div><br></div><div>Penata Desain Merek, Christo Pavlidis, dan Kepala Desainer, Juan Manuel Diaz, memperkenalkan lima model kendaraan, yaitu ES GT, EX9, EX8, EX7, dan MPV Concept. Kelima model tersebut masing-masing menghadirkan interpretasi tersendiri atas konsep Kemewahan Masa Depan. Setiap model memenuhi ekspektasi pengguna yang terus berkembang terhadap kemewahan, performa, dan teknologi mutakhir.</div><div><br></div><div>Inti dari konsep Kemewahan Masa Depan adalah Perpetua, sebuah filosofi desain yang terinspirasi dari perubahan gelombang Samudra Atlantik mengikuti cahaya, pasang surut air laut, dan waktu. Filosofi ini diwujudkan dalam dua bentuk ekspresi. Air berwujud cair merepresentasikan kecepatan dan ketegangan pada model-model yang berorientasi sporty. </div><div><br></div><div>Sementara itu, permukaan dengan garis tegas dan bentuk pahatan yang terinspirasi dari es kutub padat menjadi dasar bagi model-model kendaraan mewah masa depan. Konsep sporty dan kemewahan bukanlah dua bahasa desain yang terpisah, melainkan dua ekspresi dari estetika yang sama. Dengan demikian, bahasa desain tersebut dapat diterapkan pada berbagai kategori kendaraan.</div><div><br></div><div>EX9 merupakan model pertama yang sepenuhnya mewujudkan bahasa desain ini di segmen kendaraan mewah. Jarak sumbu roda yang panjang, overhang depan yang pendek, dan bodi yang tegak menciptakan postur SUV unggulan yang mantap. Gagang pintu yang rata dengan permukaan bodi dan garis bahu yang menyambung tanpa putus membentuk siluet menyerupai pahatan. Desain ini menonjolkan proporsi, material, dan permainan cahaya dengan ornamen seminimal mungkin.</div><div><br></div><div> EX8 menonjolkan garis-garis horizontal dan menawarkan ruang kabin yang lapang bagi konsumen SUV premium yang bepergian bersama keluarga atau rombongan. Sementara itu, EX7 mengusung elemen desain EX9 dalam bentuk yang lebih sporty. MPV Concept mengeksplorasi bentuk-bentuk desain yang melampaui sedan dan SUV konvensional, sekaligus menunjukkan fleksibilitas konsep Kemewahan Masa Depan untuk berbagai kategori kendaraan.</div><div><br></div><div>ES GT mengekspresikan sisi yang lebih dinamis dari konsep Kemewahan Masa Depan. Sebagai crossover wagon pertama EXEED, bodinya yang rendah dan memanjang menciptakan kesan seolah-olah kendaraan sedang bergerak maju, bahkan saat diam. Di bagian interior, kokpit simetris dengan desain melengkung dilengkapi Sky Screen dan layar tengah yang melayang. Sementara itu, jok sport terintegrasi memberikan penopang samping aktif. Desain sportynya juga tercermin dalam pengalaman berkendara, menghadirkan DNA balap EXEED ke dalam kabin.</div><div><br></div><div>Setelah acara tersebut, tim desain mengadakan lokakarya bersama perwakilan pengguna dari berbagai negara. Masukan mereka akan membantu EXEED memahami kebutuhan pengguna dengan lebih baik. Dengan memanfaatkan teknologi parkir pintar SIVP, Texxeract, dan DNA balapnya, EXEED tengah membentuk visi baru tentang mobilitas di pasar global melalui desain, performa, dan teknologi mutakhir.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 21:28:00 +0700</pubDate>
</item>
<item>
<title>Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding EUR 0.5 Billion</title>
<link>https://relleaseid.com/berita-bisnis/Global-Pharmaceutical-Company-Commits-to-a-Dual-Site-Deal-with-AGC-Biologics-Exceeding-EUR-0-5-Billion</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/1391_Global-Pharmaceutical-Company-Commits-to-a-Dual-Site-Deal-with-AGC-Biologics-Exceeding-EUR-0-5-Billion.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Agreement builds on customer&#039;s long-term deal in new Yokohama facility for five commercial biologics programs, now allocating an additional six commercial programs to Copenhagen facility to consolidate high-volume, single-use biologics manufacturing with one global partner&nbsp;</div><div><br></div><div>Deal reflects a shared belief that site interoperability and dual submissions are key to unlocking the benefits of local manufacturing for a global supply</div><div><br></div><div>Running multiple sites as one integrated supply node lets both companies move production quickly between locations as needs change</div><div><br></div><div>COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- AGC Biologics has expanded its existing long-term manufacturing agreement with a global pharmaceutical company, adding a second supply node at the CDMO&#039;s Copenhagen facility. The expansion, which builds on the existing agreement anchored at AGC Biologics&#039; Yokohama site, grows the deal&#039;s total value beyond EUR 0.5 billion.</div><div><br></div><div>The expanded deal calls for multi-product drug substance manufacturing across six biologics programs at AGC Biologics&#039; Copenhagen site, encompassing process transfer, scale-up, validation, and commercial production. Products will launch and move across facilities with several dual regulatory submissions to optimize capacity, cost, and local manufacturing benefits, capturing levels of flexibility and supply chain robustness that could not be achieved with a single-site supply arrangement.&nbsp;</div><div><br></div><div>"This customer is building a more resilient, more flexible supply chain, and they&#039;ve chosen to do that with us across two continents. This is exactly what we&#039;re well-positioned to offer to a market craving geographic flexibility and regionalization, while retaining global supply," said Alberto Santagostino, President and CEO of AGC Biologics. "We&#039;ve built our single-use strategy around quality, capacity, and deep technical expertise so that when a partner is ready to localize and scale, we can meet them where they are. This deal takes inter-site flexibility to a larger scale, but it builds on our existing experience: two of our customers have already decided to co-launch their products from both our Seattle and Copenhagen facilities."</div><div><br></div><div>This agreement further cements AGC Biologics as a prominent global player in single-use bioreactor manufacturing, serving the large-scale mammalian single-use manufacturing needs of major pharmaceutical companies across regions. AGC Biologics maintains one of the largest global networks of single-use manufacturing capacity by volume in the industry, according to BDO&#039;s bioTRAK database.</div><div><br></div><div> By combining strong commercialization capabilities with a friendly and expert CDMO approach, AGC Biologics supports customers pursuing cross-site launches, geographic flexibility, and regionalized manufacturing strategies across its global network.</div><div><br></div><div>"For a customer to bring six additional programs to Copenhagen, after bringing five to Yokohama, tells you everything about the trust our team has earned across the network," said Tadashi Murano, President of AGC Life Science Company. "Our focus stays on building lasting and trust-based relationships with our pharmaceutical customers, like we have been doing for decades in AGC with our industrial partners across a wide range of industries including electronics and automotive."</div><div><br></div><div>Frequently Asked Questions (FAQs)</div><div><br></div><div>Why isn&#039;t the customer named in this announcement?</div><div><br></div><div>Consistent with standard practice in the biopharmaceutical industry, customer names are not disclosed without the customer&#039;s consent. AGC Biologics regularly enters into confidential manufacturing agreements to protect its customers&#039; competitive and regulatory strategies.</div><div><br></div><div>Could this customer expand its manufacturing relationship with AGC Biologics further?</div><div><br></div><div>AGC Biologics operates GMP manufacturing sites across the U.S., Europe, and Asia, providing capacity for customers to expand into additional regions as their commercial manufacturing needs evolve.</div><div><br></div><div>What does AGC Biologics&#039; Copenhagen site offer to large-scale developers?</div><div><br></div><div>Scientific teams at AGC Biologics&#039; Copenhagen site have 25 years of expertise in drug substance development and GMP manufacturing. Customers using the site have received a total of over 50 commercial approvals from more than 20 regulatory agencies.&nbsp;</div><div><br></div><div>The Copenhagen site expansion in 2024 included 18,000 square meters distributed across manufacturing, quality control laboratories and technical and warehouse areas, including:</div><div><br></div><div>Eight 2,000-liter single-use bioreactor production lines</div><div>One 500-liter perfusion bioreactor</div><div>Two downstream purification lines</div><div><br></div><div>About AGC Biologics</div><div><br></div><div>AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. </div><div><br></div><div>Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.&#039;s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 18:55:00 +0700</pubDate>
</item>
<item>
<title>Arla Foods Ingredients and wheyco to exhibit together at Fi Europe under &#039;Growing Stronger Together&#039; theme</title>
<link>https://relleaseid.com/berita-bisnis/Arla-Foods-Ingredients-and-wheyco-to-exhibit-together-at-Fi-Europe-under---039-Growing-Stronger-Together--039--theme</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/1204_Arla-Foods-Ingredients-and-wheyco-to-exhibit-together-at-Fi-Europe-under---039-Growing-Stronger-Together--039--theme.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>FRANKFURT, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients and wheyco, DMK Group&#039;s whey business, are to exhibit together at a trade event for the first time since the merger of their parent companies.</div><div><br></div><div>On 1st June, Arla Foods and DMK Group came together to form Europe&#039;s largest dairy cooperative. At Fi Europe (17th-19th November in Frankfurt), Arla Foods Ingredients, a subsidiary of Arla Foods, will demonstrate how the merger has created a stronger ingredients business.</div><div><br></div><div>The DMK Group and Arla Foods Ingredients stands will be located opposite one another, both carrying the message &#039Growing Stronger Together&#039;, with DMK&#039;s subsidiary wheyco represented on the Arla Foods Ingredients stand.</div><div><br></div><div>Anne Widart, Vice President, Commercial, at Arla Foods Ingredients said: "One of the many benefits of the merger has been the creation of an ingredients powerhouse. It has unlocked new synergies and opportunities, allowing us to build something even better for the future. Fi Europe is the perfect platform to demonstrate our shared ambitions."</div><div><br></div><div>Earlier this year, Arla Foods Ingredients debuted its &#039Targeted GLP-1 Companion Nutrition&#039; concept, demonstrating how nutrient-dense products can meet the needs of GLP-1 users. At Fi Europe, it will showcase new applications, including a spoonable yogurt, a drinking yogurt, a fermented high-protein shot and a high-protein water-based shot.</div><div><br></div><div>The &#039Unlock Permeate&#039; concept will demonstrate how Arla Foods Ingredients&#039; Variolac can improve cost-effectiveness and sensory properties in dairy, bakery and confectionery applications. Produced through nanofiltration, the whey permeate ingredient offers a mild milky taste, high cost efficiency and high content of calcium, magnesium and potassium.</div><div><br></div><div>Visitors can also sample new active nutrition solutions, including protein shakes, protein waters and the AirBar - an aerated milk protein bar with a light texture offering a new sensory experience in the protein bar category.</div><div><br></div><div>Anne Widart added: "These concepts typify Arla Foods Ingredients&#039; commitment to innovation, from GLP-1 companion nutrition and active nutrition to improving taste and cost efficiency with whey permeate. With our expertise and capabilities further enhanced by the merger, we can deliver even greater value to our customers."</div><div><br></div><div>Meanwhile, DMK Industry will showcase its fat-filled ingredients, TOPPICS, FATTICS and BATTICS, and Sweetened Condensed Milk portfolios through four indulgent concepts: cupcakes with an aerated topping, chocolate caramel cookies, chocolate espresso fudge and a Cafe Bomb?n.</div><div><br></div><div>Arla Foods Ingredients will exhibit at Stand #30J94, opposite DMK Group at #30K94.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 18:51:00 +0700</pubDate>
</item>
<item>
<title>Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated</title>
<link>https://relleaseid.com/berita-bisnis/Philips-delivers-strong-order-intake-growth--comparable-sales-growth-and-strong-margin-expansion-in-Q3--2026-outlook-reiterated</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/2321_Philips-delivers-strong-order-intake-growth--comparable-sales-growth-and-strong-margin-expansion-in-Q3--2026-outlook-reiterated.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>November 3, 2026</div><div><br></div><div>Q3 2026 Group performance</div><div><br></div><div>Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment</div><div>Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth</div><div>Income from operations of EUR 165 million</div><div>Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments</div><div>Operating cash flow of EUR 544 million; free cash flow of EUR 384 million</div><div>Respironics reached agreement in principle with the US Department of Justice</div><div>Philips reiterates its full-year 2026 outlook</div><div>Roy Jakobs, CEO of Royal Philips:</div><div>"We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.</div><div><br></div><div>We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution. These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers. We look forward to showcasing our next innovations at RSNA later this month.</div><div><br></div><div>We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The Respironics agreement in principle with the US Department of Justice marks an important step in this process.</div><div><br></div><div>Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people."</div><div><br></div><div>Group and segment performance</div><div><br></div><div>Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment. Comparable sales increased by 3%, driven by Personal Health and Connected Care.</div><div><br></div><div>Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation. Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows. Free cash flow increased to EUR 384 million.</div><div><br></div><div>Diagnosis & Treatment comparable sales growth was flat. Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2. Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.</div><div><br></div><div>Connected Care comparable sales increased by 5%, driven by growth in all businesses. Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.</div><div><br></div><div>Personal Health comparable sales increased by 8%. Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.</div><div><br></div><div>Innovation highlights</div><div><br></div><div>Philips is accelerating innovation in image-guided therapy. In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds. In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.</div><div>The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.</div><div>Philips extended its monitoring partnership with one of the largest US health systems through 2034. The national agreement covers equipment and services, expands the use of Philips&#039; Capsule platform, and supports future technology needs.</div><div>Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings. This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.</div><div>Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico&#039;s largest public healthcare institution, IMSS. The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.</div><div>Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China. The partnership will focus on clinical care, training, research and international collaboration, combining Philips&#039; diagnostic imaging and image-guided therapy capabilities with Asia Medical Group&#039;s cardiovascular expertise.</div><div>Personal Health launched innovations across oral care, beauty and mother and child care. These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent&#039;s first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.</div><div><br></div><div>Productivity</div><div><br></div><div>Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date. The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.</div><div><br></div><div>Progress on Respironics-related legal proceedings</div><div><br></div><div>Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.</div><div><br></div><div>Also in the third quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips in connection with the Respironics recall.</div><div><br></div><div>Outlook</div><div><br></div><div>Philips reiterates its full-year 2026 outlook:</div><div><br></div><div>Comparable sales growth: 3%-4.5%</div><div>Adjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%</div><div>Free cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million</div><div><br></div><div>Within the context of an uncertain macro-environment, Philips&#039; 2026 outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027. The outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General.</div><div><br></div><div>Capital allocation</div><div><br></div><div>In the third quarter, Philips issued EUR 650 million fixed rate notes due 2034 (the "Notes") under its European Medium Term Note program. The Notes are the healthcare industry&#039;s first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed, reflecting strong investor demand. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in the Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambitions. See here for more information on Philips&#039; current debt structure.</div><div><br></div><div>Further information: conference call, video webcast and website</div><div><br></div><div>Roy Jakobs, CEO, and Charlotte Hanneman, CFO, will host a conference call for investors and analysts at 10:00 am CET on November 3, 2026, to discuss the results. A live webcast will be available on the Philips Investor Relations webpage and can be accessed here. A replay and related materials, including additional information on the outlook and forward-looking statements, will be available on the Philips Investor Relations webpage.</div><div><br></div><div>About Royal Philips</div><div>Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people&#039;s health and well-being through meaningful innovation. Philips&#039; patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.</div><div><br></div><div>Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,900 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.</div><div><br></div><div>Forward-looking statements and other information</div><div><br></div><div>Forward-looking statements</div><div><br></div><div>This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips&#039; organic business and the completion of acquisitions and divestments. Forward looking statements can be identified generally as those containing words such as "anticipates", "assumes", "believes", "estimates", "expects", "should", "will", "will likely result", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.</div><div><br></div><div>These factors include, but are not limited to, macro-economic and geopolitical changes - including the war in Ukraine and ongoing tensions in the Middle East - as well as measures such as enacted and proposed tariffs and trade actions introduced in response to rising global tensions; Philips&#039; ability to keep pace with the changing health technology environment; Philips&#039; ability to gain leadership in artificial intelligence and health informatics in response to developments in the health technology industry; integration of acquisitions and their delivery on business plans and value creation expectations; ability to meet expectations with respect to ESG-related matters; securing and maintaining Philips&#039; intellectual property rights, and unauthorized use of third-party intellectual property rights; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; the resilience of our supply chain; challenges in simplifying our organization and our ways of working; attracting and retaining personnel; breach of cybersecurity; challenges in driving operational excellence and speed in bringing innovations to market; treasury and financing risks; tax risks; reliability of internal controls; compliance with regulations and standards involving quality, product safety, (cyber) security and artificial intelligence; and compliance with business conduct rules and regulations including privacy, existing and upcoming ESG disclosure and due diligence requirements. As a result, Philips&#039; actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Further information chapter included in the Annual Report 2025.</div><div><br></div><div>Third-party market share data</div><div><br></div><div>Statements regarding market share contained in this document, including those regarding Philips&#039; competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management&#039;s estimates of rankings are based on order intake or sales, depending on the business.</div><div><br></div><div>Market Abuse Regulation</div><div><br></div><div>This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.</div><div><br></div><div>Use of non-IFRS information</div><div><br></div><div>In presenting and discussing the Philips Group&#039;s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2025.</div><div><br></div><div>Presentation</div><div><br></div><div>All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2025. Certain prior year balances have been reclassified to conform to the current period presentation.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 18:43:00 +0700</pubDate>
</item>
<item>
<title>Wood Mackenzie: Middle East conflict reshapes growth, resilience and partnerships across the region&#039;s largest NOCs</title>
<link>https://relleaseid.com/berita-bisnis/Wood-Mackenzie--Middle-East-conflict-reshapes-growth--resilience-and-partnerships-across-the-region--039-s-largest-NOCs</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/2764_Wood-Mackenzie--Middle-East-conflict-reshapes-growth--resilience-and-partnerships-across-the-region--039-s-largest-NOCs.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>LONDON/HOUSTON/SINGAPORE, Nov. 03, 2026 (GLOBE NEWSWIRE) --&nbsp;&nbsp;</div><div><br></div><div>FOR IMMEDIATE RELEASE</div><div><br></div><div>Wood Mackenzie | www.woodmac.com</div><div><br></div><div>The Middle East conflict has tested ADNOC, Saudi Aramco and QatarEnergy, while highlighting sharp differences in export flexibility and portfolio diversification. Although all three companies remain resilient, the conflict has increased competing demands on capital, expertise and management attention, strengthening the role of partnerships at home and abroad.</div><div><br></div><div>Bypass routes, ship-to-ship shuttle transfers and a partial reopening of the Strait of Hormuz have allowed Aramco and ADNOC to increase combined operating cash flow by around $35 billion, or 25%, against pre-war estimates.</div><div><br></div><div>But the recovery remains fragile and bypasses carry their own risks, as Houthi attacks on the East-West pipeline and Red Sea shipping have shown. Flows through the Strait are only partly restored and the windfall depends on elevated prices. QatarEnergy has taken the biggest hit, just as the North Field expansion was due to lift liquefaction capacity from 77 to 142 mmtpa.</div><div><br></div><div>In the near term, all three NOCs are focused on restoring capacity and strengthening export resilience. Over the longer term, the conflict will reshape business development priorities - domestic resource access, partnerships and M&A - both at home and abroad.</div><div><br></div><div>"The conflict has increased the number of competing priorities facing Middle East NOCs," said Neivan Boroujerdi, Director, Corporate Research, Wood Mackenzie. "ADNOC, Aramco and QatarEnergy all face different challenges, but each is balancing domestic expansion, international growth and resilience simultaneously. Capital is not the constraint. Access to technology, markets and operational capability will shape the next phase, strengthening the role of partnerships across the sector."</div><div><br></div><div>Key findings:</div><div><br></div><div>ADNOC is leading the recovery. Freed from OPEC quotas, it is looking beyond its 5 million b/d target for 2027, with 6 million b/d mooted for the early 2030s. Hopes rest on unconventionals and additional phases at existing concessions. Its global LNG platform, formed in July 2026, targets 47 mmtpa of marketable LNG by 2035, which would rank it in the top five globally on LNG capacity. Delivering oil growth, gas self-sufficiency and international expansion simultaneously is likely to increase reliance on strategic partners and technical expertise.</div><div>Saudi Aramco&#039;s domestic gas expansion, and potential LNG exports, may open part of its upstream sector to external participation for the first time. As unconventional gas ramps up, projected sales gas supply of around 180 bcm/y in the early 2030s would outpace domestic demand of around 130 bcm/y, a surplus that could support significant LNG exports. A standalone gas entity could ring-fence gas investment from the oil business and provide a new funding vehicle for domestic gas growth and international LNG opportunities. Equity in that entity could be offered to IOCs or NOCs facilitating LNG swaps, offtake agreements and other commercial arrangements.</div><div>QatarEnergy faces the greatest strategic challenge due to long-term facility damage, lost production and continued dependence on the Strait. Repair costs could trigger IOC contract extensions, with ExxonMobil among the most exposed. The outcome for IOCs remains uncertain, potentially increasing near-term costs while extending participation. Exploration remains central to QatarEnergy&#039;s international strategy, but it should also consider development-stage acquisitions that can accelerate production growth and build technical capability.</div><div><br></div><div>Background:</div><div><br></div><div>Interest among IOCs and international NOCs in Middle East resources will remain high. Uncertain and volatile environments make low-cost barrels attractive, and the Middle East has the lowest of the lot. The region already accounts for around 15% of the Majors&#039; production today, rising to 17% by 2030. However, elevated geopolitical risk may lead some international companies to become more selective about future exposure and NOCs may need to widen their partnership pool to new entrants.</div><div><br></div><div>The conflict has reinforced the strategic rationale for international diversification in gas (ADNOC and Aramco) and exploration (QatarEnergy). But competition for non-Hormuz LNG and US gas will intensify, building on pre-war deals struck largely at or above Wood Mackenzie&#039;s&nbsp; base-case NPV10. Ultimately, internationalisation is becoming less about growth and more about resilience through diversification. As NOCs balance domestic expansion with international growth ambitions, collaboration with IOCs will be required across upstream, gas and LNG development.</div><div><br></div><div>You have received this news release from Wood Mackenzie because of the details we hold about you. If the information we have is incorrect you can either provide your updated preferences by contacting our media relations team. If you do not wish to receive this type of email in the future, please reply with &#039;unsubscribe&#039; in the subject header. &#8239;</div><div><br></div><div>About Wood Mackenzie:</div><div>Wood Mackenzie is the global leader in analytics, insights and proprietary data across the entire energy and natural resources landscape. For over 50 years our work has guided the decisions of the world&#039;s most influential energy producers, utilities companies, financial institutions and governments. Now, with the world&#039;s energy system more complex and interconnected than ever before, sector-specific views are no longer enough. </div><div><br></div><div>That&#039;s why we&#039;ve redefined what&#039;s possible with Intelligence Connected: the fusion of our unparalleled proprietary data with the sharpest analytical minds, all supercharged by Synoptic AI, to deliver a clear, interconnected view of the entire value chain. Our trusted team of 2,700 experts across 30 countries breaks siloes and connects industries, markets and regions across the globe to empower our customers to identify risk sooner, spot opportunity faster and make every decision with complete confidence.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 18:39:00 +0700</pubDate>
</item>
<item>
<title>Siam Piwat showcases the success of its China partnership strategy with Golden Week sales doubling and Thailand&#039;s only winner of Alipay+ Growth Award</title>
<link>https://relleaseid.com/berita-bisnis/Siam-Piwat-showcases-the-success-of-its-China-partnership-strategy-with-Golden-Week-sales-doubling-and-Thailand--039-s-only-winner-of-Alipay--Growth-Award</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/5036_Siam-Piwat-showcases-the-success-of-its-China-partnership-strategy-with-Golden-Week-sales-doubling-and-Thailand--039-s-only-winner-of-Alipay--Growth-Award.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Photo:&nbsp;Siam Piwat the prestigious Alipay+ Growth Award, making it the sole recipient from Thailand, and one of the only two countries in Asia recognized at Ant International&#039;s VOYAGE 2026 & Gala Dinner in Shanghai, China.</div><div><br></div><div>Expanding its global partnership ecosystem through strategic collaborations with Huawei and iQIYI enables Siam Piwat to seamlessly integrate technology, entertainment, and luxury, delivering an end-to-end tourism experience for high-value Chinese tourists.</div><div><br></div><div>BANGKOK, THAILAND - Media OutReach Newswire - 3 November 2026 - Siam Piwat Group, a leading developer and operator of world-class landmarks, including Siam Paragon, Siam Center, Siam Discovery, ICONSIAM, and Siam Premium Outlets Bangkok, has announced the remarkable success of its global partnership ecosystem strategy.</div><div><br></div><div> Through its collaboration with premier partners to expand its high-value tourist base and stimulate spending, Siam Piwat saw its Golden Week sales double year-on-year. Furthermore, the strong performance earned Siam Piwat the prestigious Alipay+ Growth Award, making it the sole recipient from Thailand, and one of the only two countries in Asia recognized at Ant International&#039;s VOYAGE 2026 & Gala Dinner in Shanghai, China.</div><div><br></div><div>Alipay+ is the unified wallet gateway of Ant International, connecting global wallets like Alipay (China) and other leading payment apps across Siam Piwat retail touchpoints, while offering direct user engagement and exclusive campaigns in-app.</div><div><br></div><div>This milestone is the outcome of partnerships with leading payment service providers, including Alipay+, WeChat Pay, and UnionPay, to curate targeted campaigns and exclusive privileges for Chinese travelers, particularly high-value visitors and enthusiasts of luxury products.</div><div><br></div><div>Building on this success, Siam Piwat has expanded its collaboration with global tech leader Huawei and China&#039;s leading entertainment platform iQIYI to bridge the platforms&#039; user bases with travel and retail experiences in Thailand, engaging visitors throughout the entire customer journey, from pre-trip inspiration to on-site spending and activities at the destination.</div><div><br></div><div>Another distinctive highlight is Siam Piwat&#039;s collaboration with Trip.com, which connects travel offers on Ctrip&#039;s WeChat Mini Program with exclusive privileges at MINISO ICONSIAM. This allows Chinese tourists to enjoy special benefits even before they arrive in Thailand. This model enables us to engage Chinese travelers during the trip-planning stage, introducing them to Siam Piwat&#039;s shopping destinations and the privileges available through the ONESIAM Global Visitor Card.</div><div><br></div><div>Chinese Partnerships Drive Transaction Growth</div><div><br></div><div>Since 2018, Siam Piwat has collaborated with Alipay+ to develop and deliver marketing campaigns, exclusive privileges, and digital payment solutions for international visitors. In the first eight months of 2026, transactions via Alipay+ grew 2.3-fold, while the number of active users surged 2.5 times compared to the same period last year.</div><div><br></div><div>During the Golden Week holiday, Siam Piwat partnered with Alipay+ and WeChat Pay to launch exclusive campaigns and tailored promotions for Chinese visitors across retail shops and luxury brands. This initiative drove a 100% year-on-year surge in sales, demonstrating the effectiveness of partnerships in boosting tourist spending.</div><div><br></div><div>As a result of these achievements, Siam Piwat was honored with the Alipay+ Growth Award as the sole winner from Thailand, one of the only two countries in Asia recognized at the VOYAGE 2026 & Gala Dinner in Shanghai, underscoring its success in driving digital transaction growth alongside its partners.</div><div><br></div><div>Partnership with Huawei for Pre-Arrival Engagement</div><div><br></div><div>Siam Piwat has expanded its tech alliance with Huawei to access Chinese consumers across their smartphone and wearable devices. This integration connects users directly to the ONESIAM Global Visitor Card, a digital membership card through which travelers can register, discover information, plan shopping itineraries, and unlock privileges from premier brands even before departing for Thailand.</div><div><br></div><div>Furthermore, travelers can sign up via a one-click WeChat Mini Program, minimizing repetitive form-filling and offering greater convenience. International visitors from other countries can also register via the official website or Huawei Wearables.</div><div><br></div><div>This initiative forms part of Siam Piwat&#039;s pre-arrival engagement strategy, designed to build brand awareness and inspire travelers right in the home country before their actual experiences at Siam Piwat&#039;s five landmarks. The program also offers year-round "always-on" privileges, ranging from best deals and luxury retail campaigns to exclusive offers, extending benefits beyond peak travel seasons.</div><div><br></div><div>Joining Forces with iQIYI to Attract Chinese Fans Through Fandom Marketing</div><div><br></div><div>Siam Piwat has also joined forces with iQIYI, China&#039;s leading streaming platform with premium Asian content, to spearhead a fandom marketing strategy under the concept of "From Screen to Real-World Experience," capitalizing on the popularity of Chinese artists and entertainment content to generate motivation for a trip to Thailand.</div><div><br></div><div>Among the pilot activities was the iQIYI Starship: Spring of The Blade Meet & Greet, which brought Chinese superstar Xu Kai to meet fans at Siam Paragon. The event generated massive social media buzz and expanded brand visibility across fan communities in mainland China and around the world. By connecting iQIYI&#039;s fan base to real-world experiences at Siam Paragon, the partnership has enhanced destination recall and inspired travel, particularly among younger generations of tourists.</div><div><br></div><div>Expanding the Global Ecosystem to Unlock New Growth Opportunities</div><div><br></div><div>Siam Piwat has been working actively to expand its global ecosystem through alliances with leading international partners across technology, tourism, payment solutions, and entertainment, including Huawei, iQIYI, Trip.com, Alipay+, WeChat Pay, and UnionPay, with the ultimate goal of connecting travelers to its ecosystem throughout every phase of their journey, from pre-trip planning to dining, lifestyle activities, and shopping in Thailand.</div><div><br></div><div>Furthermore, Siam Piwat is enhancing campaigns and exclusive privileges for high-spending travelers, especially in the luxury segment, to maximize spending potential and reinforce Siam Paragon and ICONSIAM&#039;s positions as premier luxury shopping destinations in the region.</div><div><br></div><div>This strategy reinforces Siam Piwat&#039;s position as a global destination and ecosystem developer and a partner of choice for leading global enterprises. By transforming partnership networks into concrete business results, Siam Piwat continues to attract high-quality tourists, increase spending value, and create growth opportunities for Thailand&#039;s tourism economy.</div><div><br></div><div>For more information and exclusive privileges via the ONESIAM Global Visitor Card, please visit:</div><div>Website: https://tourist.onesiam.com/en/tourist-card-privileges/</div><div>Instagram: https://www.instagram.com/onesiamglobal/</div><div><br></div><div>Siam Piwat</div><div>Siam Piwat is a leading retail and real estate developer behind Bangkok&#039;s most iconic destinations, including Siam Paragon, Siam Center, Siam Discovery, ICONSIAM, and Siam Premium Outlets Bangkok, globally recognized for pioneering experiential destinations.</div><div><br></div><div>For over six decades, Siam Piwat has been renowned for creating iconic destinations and world-class experiences, continuously redefining Bangkok&#039;s retail landscape through award-winning developments that set new global benchmarks. Guided by creativity, innovation, and sustainability, the company continues to lead with a bold vision that inspire, engage, and delight customers from around the world, while creating long-term value for society, businesses, and future generations.</div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Hashtags: #SiamPiwat #ONESIAMGlobalVisitorCard #ONESIAMGlobal #GlobalPartnershipEcosystem #GlobalDestination #TourismEconomy</div><div><br></div><div>https://www.siampiwat.com/en/home</div><div>https://www.linkedin.com/company/siam-piwat/</div><div>https://www.facebook.com/siampiwat.official/</div><div>https://www.instagram.com/siampiwat_official/</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 11:54:00 +0700</pubDate>
</item>
<item>
<title>Illumina selected to help bring precision medicine into everyday healthcare in Singapore</title>
<link>https://relleaseid.com/berita-bisnis/Illumina-selected-to-help-bring-precision-medicine-into-everyday-healthcare-in-Singapore</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/4025_Illumina-selected-to-help-bring-precision-medicine-into-everyday-healthcare-in-Singapore.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div><br></div><div><div>Singapore&#039;s NPM Programme Three Phases</div><div><br></div></div><div>SG-INSIGHT study will extend whole- genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore&#039;s healthcare system</div><div><br></div><div>SINGAPORE - Media OutReach Newswire - 3 November 2026 - Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore&#039;s National Precision Medicine (NPM) programme. </div><div><br></div><div>Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.</div><div><br></div><div>The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore&#039;s public healthcare system, and help healthcare become more tailored to individuals over time.</div><div><br></div><div>"Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina&#039;s technology, expertise and longstanding presence in Singapore to help make that vision possible."</div><div><br></div><div>"Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore&#039;s ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population."</div><div><br></div><div>Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. Co-located with Illumina&#039;s manufacturing and R&D operations, the facility will seek the necessary accreditation and comply with Singapore&#039;s Healthcare Services Act 2020 (HCSA), strengthening its commitment to quality, safety, regulatory compliance and biomedical innovation.</div><div><br></div><div>Illumina&#039;s selection for the SG-INSIGHT Study was awarded through an international competitive tender. It builds on an existing multi-year engagement, through which Illumina supported the successful implementation and delivery of NPM Phase II, PRECISE-SG100K, covering more than 100,000 genomes from healthy volunteers.</div><div><br></div><div>"For nearly two decades, Singapore has been one of Illumina&#039;s most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore&#039;s leadership in precision health with Illumina&#039;s local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region."</div><div><br></div><div>Illumina established its presence in Singapore in 2008. Today, Singapore serves as the company&#039;s Asia Pacific regional headquarters and one of its largest hubs outside the United States, with more than 1,700 employees across three locations. Illumina operations in Singapore encompass commercial operations, manufacturing, and R&D, supporting global research and innovation across sequencing platforms, software, and emerging technologies.</div><div><br></div><div>About PRECISE</div><div>Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore&#039;s multi-phase National Precision Medicine (NPM) programme. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.</div><div><br></div><div>PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).</div><div><br></div><div>www.npm.sg</div><div><br></div><div>About Illumina</div><div>Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Hashtags: #Illumina #PRECISE</div><div><br></div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 11:48:00 +0700</pubDate>
</item>
<item>
<title>Vision Action Fund Awards 24 Governments $10M+ to Transform Basic Eye Care and Expand Reading Glasses Access</title>
<link>https://relleaseid.com/berita-bisnis/Vision-Action-Fund-Awards-24-Governments--10M--to-Transform-Basic-Eye-Care-and-Expand-Reading-Glasses-Access</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/2806_Vision-Action-Fund-Awards-24-Governments--10M--to-Transform-Basic-Eye-Care-and-Expand-Reading-Glasses-Access.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Awarded governments will make vision screening, specialist referral and reading glasses part of the health services people already use</div><div>Antigua and Barbuda, Nov. 02, 2026 (GLOBE NEWSWIRE) -- More than 2 billion people globally live with vision impairment. For 1 billion of them, their sight loss is entirely preventable or treatable, but basic eye care is often unaffordable or inaccessible. </div><div><br></div><div>Announced today, Vision Action Fund is committing a minimum of $10 million in multi-year catalytic funding to 24 governments to integrate near-vision services and basic eye care into their healthcare systems and expand access to eyeglasses. The Global Vision Impact Awards were presented at the Global Summit for Eye Health by Vision Action Fund and Vital Strategies.&nbsp;</div><div><br></div><div>"Integrating basic eye health services into community health and primary healthcare ensures people get the continuity of care they need throughout their lives," said&#8239;Abigail Steinberg, Executive Director, Vision Action Fund. "Our gratitude to the Government of Antigua and Barbuda, The International Agency for the Prevention of Blindness (IAPB), and World Health Organization for hosting the first-ever Global Summit for Eye Health and for your foundational and unwavering dedication to bring eye health to everyone, everywhere."&nbsp;&nbsp;</div><div><br></div><div>The awarded governments include Bangladesh, Cambodia, Cameroon, Chad, Ethiopia, Ghana, Madhya Pradesh (India), Indonesia, Kenya, Malaysia, Mauritania, Mexico, Mozambique, Nepal, Nigeria, Peru, Rwanda, Somalia, South Africa, Sri Lanka, Sudan, Uganda, Vietnam, and Zambia.&nbsp;</div><div><br></div><div>"I am encouraged by the commitment governments are making to improving access to essential eye care, and what this will mean for millions of people whose livelihoods and quality of life depend on clear vision," said Dr. Mary-Ann Etiebet, President and CEO, Vital Strategies. "By integrating basic eye care into primary health care, including routine screening for conditions such as diabetes and hypertension, governments can reach more people, identify vision problems earlier, and expand access to affordable solutions. We are proud to work alongside Vision Action Fund in partnership with governments to strengthen the policies and systems needed to make these commitments a sustainable reality."&nbsp;</div><div><br></div><div>Costing less than US$1 to make, reading glasses can increase personal income up to 33%, but policy and regulatory barriers deny access to hundreds of millions. The Global Vision Impact Awards operate in two phases. In the first, governments enact policies that expand access to primary eye care, such as: authorizing over-the-counter sales of reading glasses; expanding the network of primary and community health workers who can screen, refer, and dispense reading glasses; and eliminating tariffs and taxes on glasses.</div><div><br></div><div>In the second phase, countries scale up implementation nationally. The Vision Action Fund and partners will provide additional support and a supply of reading glasses for people living with age-related near-vision loss, or presbyopia. Once these strategies scale, governments could reach more than 100 million people and unlock tens of billions in economic productivity.</div><div><br></div><div>"For millions of Nigerians, including an estimated 25 million with presbyopia, eye screening and reading glasses will soon be within reach at their local point of care," said the Honourable Minister of State for Health and Social Welfare, Dr. Iziaq Adekunle Salako. "Nigeria&#039;s Presidential Initiative has already provided reading glasses to more than 1 million people through primary healthcare channels, and we commit to expanding our reach to 3 million more people over the next 3 years. We are grateful for The Global Vision Impact Award, which recognizes this momentum and partners with us to expand even further, bringing screening, referral, and reading glasses to the last mile. With this initiative, we are demonstrating to the world an effective model for delivering primary eye care at scale."</div><div><br></div><div>"We must make eye health part of everyday health care, everywhere," said Peter Holland, CEO, International Agency for the Prevention of Blindness. "That&#039;s why we are proud to convene the first-ever Global Summit for Eye Health to transform the way the world sees the value of vision. We commend the governments who have made the social, economic and health commitments to build a world where millions of people have access to quality eye care. Together, they demonstrate growing recognition that investing in eye health is an investment in human potential, economic growth, and sustainable development."</div><div><br></div><div>Vision Action Fund partners with Vital Strategies and national and local governments in the awarded countries to integrate eye care into community-level services, streamline retail access to reading glasses, and align policies with the&#8239;WHO&#039;s SPECS 2030 targets, which call for a 40 percentage-point increase in effective refractive error coverage by 2030.</div><div>&nbsp;</div><div>About Vision Action Fund&nbsp;</div><div>Vision Action Fund is working to expand access to basic eye care and make reading glasses a routine, self-sustaining part of life across low- and middle-income countries. Incubated by the Livelihood Impact Fund, we partner with governments, health systems, community-based networks, and private markets to unlock investment, drive systems change, and help restore tens of millions of adults&#039; livelihoods, income, and independence. Visit www.visionactionfund.org and follow us on LinkedIn.</div><div><br></div><div>About Vital Strategies&#8239;</div><div>Vital Strategies is a global health organization that believes every person should be protected by an equitable and effective public health system. We work with governments, communities and organizations around the world to reimagine public health so that health is supported in all the places we live, work and play. The result is millions of people living longer, healthier lives.&#8239;&nbsp;</div><div>To find out more, please visit&#8239;www.vitalstrategies.org&#8239;or&#8239;follow us on LinkedIn.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 07:17:00 +0700</pubDate>
</item>
<item>
<title>onsemi to Acquire Ferric, Establishing Leadership in Power Delivery for Next-Generation AI Processors</title>
<link>https://relleaseid.com/berita-bisnis/onsemi-to-Acquire-Ferric--Establishing-Leadership-in-Power-Delivery-for-Next-Generation-AI-Processors</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/2172_onsemi-to-Acquire-Ferric--Establishing-Leadership-in-Power-Delivery-for-Next-Generation-AI-Processors.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>Acquisition expands AI Data Center revenue opportunity&nbsp;</div><div><br></div><div>News Highlights:</div><div><br></div><div>*Establishes onsemi as a leader in integrated voltage regulator (IVR) technology with best-in-class power density required for next-generation AI processors</div><div>*Combines Ferric&#039;s engineering talent with expertise in magnetics and power conversion with onsemi&#039;s productization capabilities, operating scale and customer relationships</div><div>*Raises onsemi&#039;s 2030 AI data center revenue target by $500 million to greater than $3 billion, with acceleration thereafter</div><div>*Expected to be accretive to onsemi&#039;s long-term revenue growth, gross margin, and EPS targets at scale</div><div><br></div><div>SCOTTSDALE, Ariz., Nov. 02, 2026 (GLOBE NEWSWIRE) -- onsemi (Nasdaq: ON) today announced that it has entered into an agreement to acquire Ferric, Inc., an innovator in integrated voltage regulator (IVR) technology, for $600 million in cash, plus up to $175 million in contingent consideration upon achievement of certain revenue milestones. </div><div><br></div><div>The acquisition will strengthen onsemi&#039;s leadership in power delivery to AI processors by adding differentiated power density, efficiency and transient response capabilities, further enhancing the company&#039;s portfolio from grid to core. As a result, onsemi is raising its 2030 AI data center revenue target by $500 million to greater than $3 billion, and expects multi-year accelerated growth in its IVR business thereafter.</div><div><br></div><div>"The rapid growth of AI is reshaping the requirements for power delivery to increasingly capable and power-intensive processors," said Hassane El-Khoury, President and CEO of onsemi. "Combined with onsemi&#039;s broad power portfolio, this strategic acquisition will strengthen our leadership position while expanding our content opportunity and ability to support customers as AI processor architectures continue to evolve."</div><div><br></div><div>"Ferric was founded to rethink how power is delivered at the point of compute," said Noah Sturcken, Founder and Chief Executive Officer of Ferric. "We believe integrated power architectures will play an increasingly important role in the future of AI data centers. Joining onsemi gives us the scale, manufacturing capabilities and customer reach needed to accelerate adoption and bring these technologies into the mainstream."</div><div><br></div><div>AI Power Demands Accelerate the Transition to IVR</div><div><br></div><div>As processor power continues to scale, the industry is moving voltage regulation progressively closer to the processor to reduce losses, increase power density and respond faster to rapidly changing power demands. IVRs represent the next step in this evolution by integrating power conversion directly into the processor package or substrate.</div><div><br></div><div>Ferric is at the forefront of this transition with highly differentiated IVR technology that integrates the power controller, FETs, inductors and capacitors into a single compact package. This architecture reduces board area by 50-70% compared with conventional discrete voltage regulator solutions while delivering more power closer to the processor. As a result, customers can dedicate a greater share of system power to AI compute, improving tokens per watt for increasingly power-intensive processors. By adding these capabilities, onsemi is positioned for leadership in AI processor power delivery architectures.</div><div><br></div><div>Ferric brings more than a decade of specialized engineering expertise in integrated voltage regulation and advanced magnetics, backed by a portfolio of more than 40 patents. By combining Ferric&#039;s differentiated technology with onsemi&#039;s productization capabilities, operating scale and broad customer relationships, the acquisition will establish onsemi as a leader in power delivery to next-generation AI processors and advance the commercialization of these technologies at scale.</div><div><br></div><div>Transaction Details</div><div><br></div><div>Under the terms of the agreement, onsemi will acquire Ferric for $600 million in cash at closing, plus up to $175 million in additional cash consideration tied to the achievement of revenue milestones. The transaction will be funded with cash on hand. Approximately 50 Ferric employees, primarily located in New York and Silicon Valley, are expected to join onsemi. The transaction is expected to close by the end of 2026, subject to customary closing conditions, and is expected to be accretive to onsemi&#039;s long-term revenue growth and gross-margin targets at scale. onsemi expects no meaningful near-term financial impact from this transaction.</div><div><br></div><div>More Information</div><div><br></div><div><a href="https://investor.onsemi.com/static-files/1f3489c0-109a-46a1-b32d-e72479d3210f" target="_blank">Investor Presentation</a></div><div><br></div><div>Advisors</div><div><br></div><div>Barclays served as exclusive financial advisor to onsemi. Morrison & Foerster LLP served as legal counsel to onsemi. UBS Investment Bank served as exclusive financial advisor and Cooley LLP served as legal counsel to Ferric, Inc.</div><div><br></div><div>About onsemi</div><div>onsemi (Nasdaq: ON) delivers intelligent power and sensing technologies that enable electrification, energy efficiency, safety, and automation across automotive, industrial, and AI data center end&#8209;markets. With a highly differentiated and innovative product portfolio, onsemi helps customers solve complex challenges to achieve higher efficiency, improved performance, and lower system cost, while supporting a safer, cleaner, and more energy&#8209;efficient world. The company is part of the S&P 500? index. Learn more at www.onsemi.com.</div><div><br></div><div>About Ferric</div><div>Ferric is a leading innovator in Integrated Voltage Regulator (IVR) solutions, specializing in advanced power conversion technologies designed to optimize power delivery in next-generation computing systems. By providing dynamic control over power at the core level, Ferric enables greater computational density, higher efficiency and smarter performance across a wide range of industries. With proven reliability and system-level impact, Ferric&#039;s solutions play a pivotal role in unlocking the potential of tomorrow&#039;s most demanding technologies.</div><div><br></div><div>onsemi and the onsemi logo are trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders.</div><div><br></div><div>Caution Regarding Forward-Looking Statements:</div><div>This press release includes "forward-looking statements," as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. </div><div><br></div><div>All statements, other than statements of historical facts, included or incorporated in this press release could be deemed forward-looking statements, particularly statements about the consummation and anticipated benefits of the proposed acquisition of Ferric, including but not limited to: forecasts about the pace, scale and direction of technological change and its impact on onsemi&#039;s total addressable market opportunity; statements about onsemi&#039;s ability to capitalize on such an opportunity; and the potential impact of each of the foregoing on onsemi&#039;s operating results and financial condition. </div><div><br></div><div>Forward-looking statements are often characterized by the use of words such as "believes," "estimates," "expects," "projects," "may," "will," "intends," "plans," "anticipates," "should" or similar expressions or by discussions of strategy, plans or intentions. All forward-looking statements in this document are made based on onsemi&#039;s current expectations, forecasts, estimates and assumptions and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. </div><div><br></div><div>Certain factors that could affect our future results or events are described under Part I, Item 1A "Risk Factors" in the 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 9, 2026 (the "2025 Form 10-K") and from time to time in onsemi&#039;s other SEC reports. Readers are cautioned not to place undue reliance on forward-looking statements. onsemi assumes no obligation to update such information, which speaks only as of the date made, except as may be required by law.</div><div><br></div><div> Investing in onsemi&#039;s securities involves a high degree of risk and uncertainty, and you should carefully consider the trends, risks and uncertainties described in this document, onsemi&#039;s 2025 Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to onsemi&#039;s securities. If any of these trends, risks or uncertainties actually occurs or continues, onsemi&#039;s business, financial condition or operating results could be materially adversely affected, the trading prices of onsemi&#039;s securities could decline, and you could lose all or part of your investment. All forward-looking statements attributable to onsemi or persons acting on onsemi&#039;s behalf are expressly qualified in their entirety by this cautionary statement.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 07:11:00 +0700</pubDate>
</item>
<item>
<title>Make Celebrations Extraordinary: 1664 and CLOT Unveil the Next Chapter of the East-Meets-French Story in Asia</title>
<link>https://relleaseid.com/berita-bisnis/Make-Celebrations-Extraordinary--1664-and-CLOT-Unveil-the-Next-Chapter-of-the-East-Meets-French-Story-in-Asia</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/4615_Make-Celebrations-Extraordinary--1664-and-CLOT-Unveil-the-Next-Chapter-of-the-East-Meets-French-Story-in-Asia.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>The latest partnership introduces limited-edition designs and curated experiences this festive season, bringing a new spirit of celebration to the region</div><div><br></div><div>HONG KONG SAR - Media OutReach Newswire - 2 November 2026 - Carlsberg Asia today announced the next chapter of 1664&#039;spartnership with CLOT, launching the festive campaign "Make Celebrations Extraordinary" across the Chinese Mainland, Singapore, Malaysia and Vietnam from November 2026 through February 2027.</div><div><br></div><div>Building on the partnership&#039;s successful debut Hong Kong last year, 1664, the world&#039;s No. 1* French beer brand, and CLOT, the pioneering fashion label founded by Edison Chen, are expanding the East-Meets-French story to a wider audience. The partnership introduces limited-edition 1664 x CLOT beer cans and exclusive merchandise, alongside a series of curated experiences that bring Asia a new way to celebrate across cultures and occasions.</div><div><br></div><div>Arindam Varanasi, Commercial Vice President, Carlsberg Asia, said: "The success of our first collaboration with CLOT proved that when 1664 shows up in culture, consumers respond. This year, we are expanding the partnership into the Chinese Mainland which is our largest market - a further step in strengthening our premium portfolio in Asia. By fusing CLOT&#039;s dynamic energy with 1664&#039;s French heritage, we are bringing our &#039;unquestionably good taste&#039; spirit to life and redefining celebration across the region."</div><div><br></div><div>Make Celebrations Extraordinary: From Design to Moments</div><div><br></div><div>At the heart of the campaign is CLOT&#039;s signature Silk Royale pattern, a motif inspired by the elegance of Chinese silk, its intricate geometric lines referencing luxurious jacquard with a modern edge. For this collaboration, the pattern is reimagined in vibrant festive hues, flowing across 1664&#039;s iconic blue-and-white design in a visual dialogue between Asian tradition and French audacity.</div><div><br></div><div>Anchored by 1664&#039;s signature cocarde, a nod to the brand&#039;s French heritage and brewing craftsmanship, the 1664 x CLOT design motifs commemorate this special time of year. Exclusively for this collaboration, the CLOT&#039;s iconic Silk Royale pattern is reimagined in a vibrant, multi-coloured treatment. Illuminated by neon-inspired outlines, the design evokes the glow and vibrant energy of Asia in blues, reds and yellows accented by firework patterns, capturing the uplifting moment when celebrations come alive with 1664.</div><div><br></div><div>The interplay between CLOT&#039;s richly coloured patterns and 1664&#039;s clean red, white and blue palette creates a contemporary elegance that captures the spirit of celebration in style, where East meets French and tradition meets modernity.</div><div><br></div><div>Beyond the beer cans, the 1664 x CLOT design motifs extend to a range of exclusive merchandise. The key highlight is a bespoke apparel collection curated by CLOT for the campaign, including T-shirts, socks and caps, each piece infused with festive vibrancy and the collaboration&#039;s East-meets-French spirit, bringing the partnership to life beyond the taste and into the moments people share.</div><div><br></div><div>The 1664 x CLOT limited-edition products are available from November 2026 through February 2027 in selected supermarkets, bars, restaurants and online across Chinese Mainland, Singapore, Malaysia and Vietnam. A series of on-the-ground activations and market-exclusive premiums will also be rolled out throughout the season, inviting consumers to immerse themselves in festive experiences that make their celebrations extraordinary. For more information, please visit https://www.1664blanc.com/.</div><div><br></div><div>*GlobalData 2025 research for 2023, based on actual volume sales data in The Hectolitres.</div><div><br></div><div>About Carlsberg</div><div>Established in 1847 by brewer J.C. Jacobsen, the Carlsberg Group is one of the leading brewery groups in the world, with an attractive portfolio of beer and other beverage brands. With over 37.000 employees, and with a presence in more than 150 markets, the Group has a purpose of brewing for a better today and tomorrow. Doing business responsibly and sustainably supports that purpose - and drives the efforts to deliver value for shareholders and society.</div><div><br></div><div>Carlsberg Asia is a dynamic and diverse region comprising of 8 operating markets: Cambodia, China, Hong Kong S.A.R. (Macau and Taiwan), Laos, Malaysia, Myanmar, Singapore and Vietnam. Altogether we have 35 breweries in operation and some 13,000 employees spreading across the Asian markets. The Asia Regional Office is based in Hong Kong.</div><div><br></div><div>About 1664</div><div>1664, the world&#039;s No.1 French beer brand with a rich heritage spanning over 350 years, epitomizes timeless yet playful elegance. Our brew is distinguished by its lively and refreshing taste profile, with signature citrus notes that deliver impeccable taste in every sip. Inspired by art, design and the French appreciation of life, 1664 elevates everyday moments, turning the ordinary into the extraordinary.&#8203;</div><div><br></div><div>About CLOT</div><div>First established in 2003, CLOT is a pioneering streetwear label and the brainchild of Edison Chen. Conceived from the desire to bridge East and West through thoughtfully-designed apparel and goods, the brand takes its Chinese roots to a worldwide stage, modernizing, reinterpreting, and splices motifs from traditional Chinese culture with bold graphics, exaggerated silhouettes, and a dynamic energy reflective of the new youth of Asia. CLOT has since partnered with the likes of adidas, Bang & Olufsen, Coca-Cola, fragment design, Medicom Toy, Nike, Rimowa, Supreme, St?ssy, sacai and visvim to create sold-out collaborations, solidifying its international presence in the process.</div><div><br></div><div>CLOT&#039;s vision for a borderless culture of streetwear is further manifested in JUICE, a fashion and lifestyle retailer that expresses an all-encompassing aesthetic through its curation of apparel, home goods, and more. Located in major cities around the world, JUICE can be found in Hong Kong, Shanghai, Taipei, Taichung, and online.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Hashtags: #CarlsbergAsia</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 07:07:00 +0700</pubDate>
</item>
<item>
<title>ETC Named to TIME&#039;s America&#039;s Growth Leaders 2027 List and the Philadelphia Business Journal&#039;s 2026 PHILLY&#039;s FAST 50</title>
<link>https://relleaseid.com/berita-bisnis/ETC-Named-to-TIME--039-s-America--039-s-Growth-Leaders-2027-List-and-the-Philadelphia-Business-Journal--039-s-2026-PHILLY--039-s-FAST-50</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/4357_ETC-Named-to-TIME--039-s-America--039-s-Growth-Leaders-2027-List-and-the-Philadelphia-Business-Journal--039-s-2026-PHILLY--039-s-FAST-50.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>SOUTHAMPTON, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation (OTCID: ETCC) ("ETC" or the "Company") was named to TIME&#039;s annual list of America&#039;s Growth Leaders 2027, ranking 201 among the top 500 companies. This recognition distinguishes ETC for its outstanding growth, performance, and business momentum.&nbsp;</div><div><br></div><div>TIME and market research firm Statista, determined America&#039;s Growth Leaders through an analysis of publicly traded companies headquartered in the U.S. Each company was evaluated based on revenue growth, stock performance, and financial stability.</div><div><br></div><div>ETC was also recognized in the Philadelphia Business Journal&#039;s 2026 FAST 50 list, which highlights the fastest-growing companies in the Greater Philadelphia region. This is the second consecutive year that the Company has been recognized, ranking seventh both years.</div><div><br></div><div>Robert Laurent, ETC&#039;s President and CEO stated, "Being named one of TIME&#039;s America&#039;s Growth Leaders is an indicator of the success of the strategic efforts of our entire team, in each of our business units. We are equally honored to be recognized as one of the fastest growing companies in the Greater Philadelphia region for the second year in a row."</div><div><br></div><div>About ETC</div><div>ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. </div><div><br></div><div>ETC&#039;s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC&#039;s headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.</div><div><br></div><div>Forward-looking Statements</div><div>This news release contains forward-looking statements, which are based on management&#039;s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "future", "predict", "potential", "intend", or "continue", and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. </div><div><br></div><div>Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 07:01:00 +0700</pubDate>
</item>
<item>
<title>Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-&#039;286) Following Interim Futility Analysis</title>
<link>https://relleaseid.com/berita-bisnis/Teva-to-Discontinue-Phase-2-TOPAS-MSA-Study-of-emrusolmin--TEV---039-286--Following-Interim-Futility-Analysis</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/9035_Teva-to-Discontinue-Phase-2-TOPAS-MSA-Study-of-emrusolmin--TEV---039-286--Following-Interim-Futility-Analysis.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>*Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if continued</div><div>*Comprehensive analysis and evaluation of available open-label extension data will follow</div><div>*No safety concerns were identified in the interim analysis</div><div><br></div><div>PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it will discontinue the Phase 2 TOPAS-MSA study (NCT06568237) evaluating emrusolmin (<span style="font-family: "Times New Roman"; font-size: medium;">TEV-&#039;286</span>) in adults with multiple system atrophy (MSA). </div><div><br></div><div>The decision follows a recommendation from the independent data monitoring committee (IDMC), based on a prespecified interim futility analysis. The analysis met the predefined futility criterion, indicating a low probability of the study meeting its primary efficacy endpoint if continued. This was an interim predictive assessment and not the study&#039;s final efficacy analysis. No safety concerns were identified in the interim analysis.</div><div><br></div><div>Emrusolmin is being developed in partnership with MODAG GmbH. A comprehensive analysis of the TOPAS-MSA data and available data from the open-label extension study of emrusolmin in MSA (NCT07197866) will follow. The decision announced today concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program.</div><div><br></div><div>"While we are disappointed by the outcome of this interim analysis for the Phase 2 study, we remain deeply committed to learning everything we can from these data," said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva. "We are deeply grateful to the patients, families, investigators, and study teams who contributed their time and commitment to this research. Our hope is that the science and learnings can deepen our understanding of MSA and help us determine a path forward for emrusolmin."</div><div><br></div><div>Teva will work with the TOPAS-MSA study investigators to ensure the study protocols are followed while the Phase 2 study is discontinued. Teva plans to share the TOPAS-MSA findings with the scientific community following completion of its comprehensive analysis.</div><div><br></div><div>Teva to Host Q3 Earnings Call on November 3, 2026</div><div>Teva will host its third-quarter 2026 earnings conference call on November 3, 2026 at 8:00 a.m. ET. Register here. A live webcast of the call will be available on Teva&#039;s website at: https://ir.tevapharm.com/Events-and-Presentations.</div><div><br></div><div>About the TOPAS-MSA Program</div><div>TOPAS-MSA (NCT06568237; TV56286-NDG-20039) is a randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy and safety of emrusolmin in adults with multiple system atrophy (MSA). The study was designed to enroll approximately 350 participants to receive emrusolmin 300 mg or placebo for approximately 48 weeks, followed by a four-week follow-up period. The primary endpoint is change from baseline to Week 48 in the modified Unified Multiple System Atrophy Rating Scale Part I score.</div><div><br></div><div>The separate Phase 2 open-label extension (OLE) study (NCT07197866; TV56286-NDG-20041) is designed to evaluate the long-term safety and tolerability of emrusolmin in eligible participants who completed the 48-week treatment period of TOPAS-MSA.</div><div><br></div><div>About emrusolmin</div><div>emrusolmin, also known as TEV-&#039;286, is an investigational, orally administered small molecule designed to target alpha-synuclein aggregation, one of the core pathogenic mechanisms believed to be involved in MSA. Emrusolmin is being developed in partnership with MODAG GmbH. The U.S. Food and Drug Administration granted Orphan Drug designation to emrusolmin for MSA in 2022 and Fast Track designation in September 2025.</div><div><br></div><div>About Multiple System Atrophy (MSA)</div><div>MSA is a rare neurodegenerative disorder classified clinically as "atypical parkinsonism" and belongs to the group of synucleinopathies. MSA is characterized histopathologically by abnormal deposits of the &#945;-synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells. Typically, there is a dysfunction of the autonomic nervous system, i.e., disturbances of bladder function, erectile function, intestinal mobility, or the regulation of blood pressure in combination with a movement disorder.</div><div><br></div><div> The movement disorder often presents with either Parkinson-like symptoms or a disturbance of cerebellar function, such as ataxia, gait and speech problems. In the US, EU, and Japan, MSA affects about 40,000 people (prevalence of 4 per 100,000), with about 6,000 new cases diagnosed each year (incidence of 0.6 per 100,000). Post-diagnosis life expectancy is about 6-10 years. Due to the relatively small number of affected patients and lack of effective therapy, MSA qualifies for orphan status, allowing a shorter development path. This unmet medical need for MSA disease modification is the driver to develop new therapies that could potentially impact the lives of patients.</div><div><br></div><div>About Teva</div><div>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva&#039;s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients&#039; needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.</div><div><br></div><div>Cautionary Note Regarding Forward-Looking Statements</div><div>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#039;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva&#039;s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. </div><div><br></div><div>All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "developing," "target," "may," "expand," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future performance.</div><div><br></div><div> Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to develop emrusolmin (TEV-&#039;286) for the treatment of MSA in adults; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors," "Other Information" and "Cautionary Note Regarding Forward Looking Statements." </div><div><br></div><div>Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>     ]]></description>
<pubDate>Tue, 03 Nov 2026 06:53:00 +0700</pubDate>
</item>
<item>
<title>YYForce Highlights US$21.9 Million in Reported Net Assets and Outlines Commercial Robotics and AI Platform Priorities</title>
<link>https://relleaseid.com/berita-bisnis/YYForce-Highlights-US-21-9-Million-in-Reported-Net-Assets-and-Outlines-Commercial-Robotics-and-AI-Platform-Priorities</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/5896_YYForce-Highlights-US-21-9-Million-in-Reported-Net-Assets-and-Outlines-Commercial-Robotics-and-AI-Platform-Priorities.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>YYForce presents its reported book equity alongside its market capitalization to give investors additional context for its growth plans</div><div><br></div><div>SINGAPORE, Nov. 02, 2026 (GLOBE NEWSWIRE) -- YYForce Inc. (Nasdaq: YFOR) ("YYForce" or the "Company"), a technology-enabled provider of workforce solutions and integrated facility management services, today highlighted its reported net assets of approximately US$21.9 million, compared with an estimated market capitalization of approximately US$2.1 million as of October 30, 2026, and outlined its commercial robotics and AI priorities.</div><div><br></div><div>YYForce is providing this information to help investors evaluate its reported asset base alongside its operating results, liquidity and strategy across workforce platforms, integrated facility management and service robotics.</div><div><br></div><div>Reported financial position and valuation comparison</div><div><br></div><div>As reported in the Company&#039;s Form 6-K filed on September 25, 2026, YYForce&#039;s consolidated balance sheet as of June 30, 2026, showed the following amounts.</div><div><br></div><div><table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0">
 <tbody><tr>
  <td valign="top" style="border:solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal">Balance sheet measure<o:p></o:p></p>
  </td>
  <td valign="top" style="border:solid black 1.0pt;border-left:none;mso-border-left-alt:
  solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal">Reported amount<o:p></o:p></p>
  </td>
 </tr>
 <tr>
  <td valign="top" style="border:solid black 1.0pt;border-top:none;mso-border-top-alt:
  solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal">Total assets<o:p></o:p></p>
  </td>
  <td valign="top" style="border-top:none;border-left:none;border-bottom:solid black 1.0pt;
  border-right:solid black 1.0pt;mso-border-top-alt:solid black 1.0pt;
  mso-border-left-alt:solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal">Approximately US$38 million<o:p></o:p></p>
  </td>
 </tr>
 <tr>
  <td valign="top" style="border:solid black 1.0pt;border-top:none;mso-border-top-alt:
  solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal">Equity attributable to YYForce
  shareholders (net assets)<o:p></o:p></p>
  </td>
  <td valign="top" style="border-top:none;border-left:none;border-bottom:solid black 1.0pt;
  border-right:solid black 1.0pt;mso-border-top-alt:solid black 1.0pt;
  mso-border-left-alt:solid black 1.0pt;padding:.75pt .75pt .75pt .75pt">
  <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal">Approximately US$21.9 million<o:p></o:p></p>
  </td>
 </tr>
</tbody></table>

<p class="MsoNormal"><br></p><p class="MsoNormal">As of October 30, 2026, the Company&#039;s estimated equity market capitalization was approximately US$2.1 million, equivalent to approximately 9.6% of reported equity attributable to YYForce shareholders. This represented a discount of approximately 90.4% to reported book equity. This information uses rounded amounts and reflects financial and market data from different dates.</p></div><div>Book equity does not represent unrestricted cash, tangible net assets, liquidation proceeds or an estimate of intrinsic value. Asset carrying values are subject to accounting estimates and impairment assessments. Investors should consider the full financial statements, including liabilities, operating results, cash flows and subsequent disclosures.</div><div><br></div><div>Management commentary</div><div><br></div><div>"We believe the difference between our reported book equity and public market capitalization warrants investors&#039; attention," said Mike Fu, Chief Executive Officer of YYForce. "Our responsibility is to provide clear financial information and execute our commercial strategy. We remain focused on customer delivery, disciplined capital allocation and developing our workforce, facility management and service robotics businesses."</div><div><br></div><div>"We will evaluate each investment against customer demand, available liquidity, capital requirements and expected returns," Mr. Fu added.</div><div><br></div><div>Strategic growth priorities</div><div><br></div><div>Commercial robotics expansion. Pursuing service robotics deployments and integration with hospitality and enterprise workflows, with attention to customer requirements, deployment costs and ongoing support.</div><div><br></div><div>AI-enabled facility and workforce platforms. Developing digital platform capabilities and pursuing enterprise adoption to support workforce coordination, shift delivery and facility operations.</div><div><br></div><div>Capital discipline and market transparency. Evaluating commercial deployments against customer demand, capital requirements and expected returns, while providing shareholders with clear updates on material developments.</div><div><br></div><div>YYForce will continue to assess its operating performance, financing requirements and capital allocation priorities as its business develops. Future commercial progress remains subject to operational execution, customer adoption and broader market conditions.</div><div><br></div><div>About YYForce Inc.</div><div><br></div><div>YYForce Inc. (Nasdaq: YFOR) is a technology-enabled provider of workforce solutions and integrated facility management services. The Company is developing AI-enabled workforce platforms and robotics capabilities to support frontline operations, improve productivity and address evolving customer needs.</div><div><br></div><div>For more information, visit www.yyforce.ai.</div><div><br></div><div>Forward-Looking Statements</div><div><br></div><div>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on the Company&#039;s current expectations, assumptions and information available to it as of the date of this release. Forward-looking statements can be identified by words such as "may," "will," "should," "expects," "anticipates," "plans," "intends," "believes," "estimates," "potential" or similar expressions, or the negative of these terms.</div><div><br></div><div>Forward-looking statements in this release include, but are not limited to, expectations regarding the Company&#039;s strategy, commercial deployments, platform development, operational efficiency, capital allocation and future business performance. Historical financial figures are not forward-looking statements. Reported book equity is not an indication of the price at which the Company&#039;s shares may trade or of amounts that would be realized on any sale or liquidation.</div><div><br></div><div>Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. For a more detailed discussion of risk factors, please refer to the Company&#039;s filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" section of the Company&#039;s most recent annual report on Form 20-F, as amended. YYForce undertakes no obligation to update these statements except as required by applicable law.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Tue, 03 Nov 2026 06:47:00 +0700</pubDate>
</item>
<item>
<title>Descartes&#039; Advanced Ocean Visibility Solution Now Integrated with SAP Transportation Platforms</title>
<link>https://relleaseid.com/berita-bisnis/Descartes--039--Advanced-Ocean-Visibility-Solution-Now-Integrated-with-SAP-Transportation-Platforms</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/5012_Descartes--039--Advanced-Ocean-Visibility-Solution-Now-Integrated-with-SAP-Transportation-Platforms.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div>WATERLOO, Ontario and ATLANTA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that its Descartes MacroPoint Advanced Ocean Visibility solution is now integrated with SAP Business Netwoark Freight Collaboration and SAP Business Network Global Track and Trace through a standardized connection to the Descartes Global Logistics Network (Descartes GLN). </div><div><br></div><div>The combined solution provides shippers with access to expanded multimodal visibility capabilities within their SAP transportation environments.</div><div><br></div><div>"As supply chains become increasingly global, multimodal and disruption-prone, organizations require more timely and consistent visibility across transportation modes to improve planning and execution," said Dan Cicerchi, EVP, Corporate & Operations Development at Descartes. "By bringing our ocean visibility data directly into SAP&#039;s leading transportation platforms from the Descartes GLN, shippers can gain a more complete view of global shipments, improve operational responsiveness and strengthen supply chain resilience."</div><div><br></div><div>Ocean visibility data from the Descartes GLN flows into SAP Business Network Freight Collaboration and SAP Business Network Global Track and Trace, providing near real-time container-level tracking of departures, arrivals, loading events, gate movements and other critical milestones within customers&#039; existing SAP workflows. </div><div><br></div><div>This creates a consistent visibility experience across both ocean and road transportation movements. By combining standardized APIs, harmonized data models, and continuously updated logistics event data, the combined solution simplifies deployment, delivers multimodal visibility at scale, and provides a trusted foundation for analytics, automation, and AI-driven supply chain innovation. The comprehensive testing program confirmed production-ready performance, reliable event exchange, accurate milestone tracking and robust support for complex shipment scenarios across the full shipment lifecycle.</div><div><br></div><div>The new end-to-end connection builds on the existing Descartes GLN integration with SAP Business Network Freight Collaboration, which supports processes such as carrier booking. Descartes MacroPoint Advanced Ocean Visibility is available on the SAP? Store.</div><div><br></div><div>SAP Store, found at store.sap.com, delivers a simplified and connected digital customer experience for finding, trying, buying and renewing more than 2,300 solutions from SAP and its partners. There, customers can find the SAP solutions and SAP-validated solutions they need to grow their business. And for each purchase made through SAP Store, SAP will plant a tree.</div><div><br></div><div>Descartes is a partner in the SAP PartnerEdge program. The SAP PartnerEdge program provides the enablement tools, benefits and support to facilitate building high-quality, disruptive applications focused on specific business needs ? quickly and cost-effectively.</div><div><br></div><div>About Descartes</div><div><br></div><div>Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.</div><div><br></div><div>SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.</div><div><br></div><div>Descartes Media Contact</div><div>Andra Schaz</div><div>aschaz@descartes.com</div><div><br></div><div>Cautionary Statement Regarding Forward-Looking Statements</div><div><br></div><div>This release contains forward-looking information within the meaning of applicable securities laws ("forward-looking statements") that relate to Descartes&#039; solution offerings and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, "Certain Factors That May Affect Future Results" in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes&#039; most recently filed annual and interim management&#039;s discussion and analysis which are available under Descartes&#039; profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management&#039;s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, we do not undertake or accept any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Mon, 02 Nov 2026 21:07:00 +0700</pubDate>
</item>
<item>
<title>*HKTB Launches &quot;Hong Kong Gourmet Month&quot; to Keep the Wine &amp; Dine Buzz Going Covering 400 Restaurants .......  </title>
<link>https://relleaseid.com/berita-bisnis/-HKTB-Launches--quot-Hong-Kong-Gourmet-Month-quot--to-Keep-the-Wine--amp--Dine-Buzz-Going-Covering-400-Restaurants----------</link>
<description><![CDATA[<img src=https://relleaseid.com/photo/berita/dir112026/1559_-HKTB-Launches--quot-Hong-Kong-Gourmet-Month-quot--to-Keep-the-Wine--amp--Dine-Buzz-Going-Covering-400-Restaurants----------.jpg border=0 hspace=5 align=left width=350 /><div><br></div><div><div>*HKTB Launches "Hong Kong Gourmet Month" to Keep the Wine & Dine Buzz Going Covering 400 Restaurants and Bars Across the City from Lunch to Late Night Locals and Visitors Invited to Spend in Hong Kong and "Taste the World&#039;s Best"</div><div><br></div></div><div>HONG KONG, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Hot on the heels of its spectacular annual event, the "Hong Kong Wine & Dine Festival", the Hong Kong Tourism Board (HKTB) today launched "Hong Kong Gourmet Month". </div><div><br></div><div>Throughout November, HKTB will join hands with more than 400 restaurants, bars and food and beverage (F&B) outlets across the city to present limited-time menus, dining offers and unique experiences. The campaign invites locals and visitors to explore different districts in search of great food and "Taste the World&#039;s Best" anytime, anywhere, every day.</div><div><br></div><div>The campaign features five themed dining experiences, ranging from star-rated dining, neighbourhood delicacies and distinctive drinks to authentic local late-night bites after 9pm, easily unlocking the many flavours found "Only in Hong Kong". In addition, participants in the "Hong Kong Wine & Dine Festival" can enjoy more than 250 additional exclusive privileges across the city with the "Gourmet Month Privilege Card" distributed at the venue.</div><div><br></div><div>Dr Peter Lam, Chairman of HKTB, said, "The &#039Hong Kong Wine & Dine Festival&#039; has drawn to a successful close, attracting visitors from around the world as well as locals, and fully showcasing Hong Kong&#039;s appeal as an international culinary capital. The &#039Hong Kong Gourmet Month&#039; now takes the benefits of the Festival further, extending them across the city. Its five themes bring together star-rated restaurants, renowned neighbourhood eateries, distinctive bars and late-night hotspots, enabling visitors and locals to enjoy Hong Kong&#039;s dining scene from day to night, every day in November. We hope the campaign will give locals and visitors alike even more reasons to explore our neighbourhoods and spend locally, creating more business opportunities for the F&B and tourism-related sectors, and fully unleashing the synergies of the mega-event economy."</div><div><br></div><div>Enjoy More than 250 Exclusive Privileges Across the City with the "Gourmet Month Privilege Card"</div><div><br></div><div>With the "Gourmet Month Privilege Card" distributed at the "Hong Kong Wine & Dine Festival", locals and visitors can enjoy more than 250 exclusive privileges at designated restaurants, bars and participating F&B merchants across the city, including offers on selected menus, dining discounts, welcome drinks, buy-one-get-one-free deals and event redemptions.</div><div><br></div><div>Five Themed Dining Experiences at "Hong Kong Gourmet Month" Let Locals and Visitors Explore Flavours from Lunch to Late Night</div><div><br></div><div>"Hong Kong Gourmet Month" features five themed dining experiences, including the "Hong Kong Wine-Pairing Award-Winning Restaurants Gala", crafted by award-winning chefs and top sommeliers; "Taste More Hong Kong", offering renowned Michelin dishes at up to 30% off; as well as the "Hong Kong Late-Night Dining Guide", "Cocktail Fest Month" and "Sip and Savour in LKF", which invite locals and visitors to explore Hong Kong&#039;s dining scene as it comes alive after dark.</div><div><br></div><div>Theme 1: Hong Kong Wine-Pairing Award-Winning Restaurants Gala</div><div><br></div><div>Star chefs and sommeliers join forces to create 15 wine-pairing menus available only during Gourmet Month.</div><div><br></div><div>The "Hong Kong Wine-Pairing Award-Winning Restaurants Gala: When Top Sommeliers Meet Legendary Chefs" brings together around 15 of Hong Kong&#039;s top restaurants, including Michelin three-star Tang Court; Michelin two-star Arbor; and Michelin one-star Tosca di Angelo and And&#333;. Drawing on the ingredients, cooking methods and flavours of each dish, as well as the characteristics of each wine, their renowned chefs and sommeliers have specially curated 15 wine-pairing menus available exclusively during "Hong Kong Gourmet Month".</div><div><br></div><div> At Tosca di Angelo, for example, dishes featuring ingredients such as Mediterranean tuna, Hokkaido scallops, Mediterranean sea bream and Cherry Valley duck are paired with selected wines from Abruzzo, Marche and Sicily, allowing diners to savour the terroirs and flavours of different Italian wine regions in a single meal.</div><div><br></div><div>Theme 2: Taste More Hong Kong (Michelin dishes at up to 30% off)</div><div><br></div><div>From Michelin three-star restaurants to harbour-view venues, more than 200 restaurants are offering limited-time lunch and dinner menus, with up to 30% off selected menus.</div><div><br></div><div>The line-up includes Michelin three-star Forum Restaurant; two-star Ying Jee Club and Bo Innovation; and one-star Hansik Goo, Man Wah, Shang Palace, Epure, and Racines. Dining options span traditional Cantonese cuisine, innovative Chinese dishes, international flavours, local neighbourhood specialities and harbour-view dining experiences.</div><div><br></div><div>AFTER 9 : The Later It Gets, the Better It Tastes</div><div><br></div><div>Theme 3: Hong Kong Late-Night Dining Guide</div><div><br></div><div>More than 100 restaurants and bars lead the way to the diverse flavours of Hong Kong, the city that never sleeps.</div><div><br></div><div>The "Hong Kong Late-Night Dining Guide" brings together nearly 80 F&B brands and more than 100 outlets across districts including Central and Sheung Wan, Wan Chai, Causeway Bay, Tsim Sha Tsui, Mongkok, Sham Shui Po and Kowloon City, offering exclusive deals after 9pm. Dining options range from dai pai dong (open-air food stalls), hotpot restaurants, izakayas, burger joints and dessert shops to hotel restaurants, harbour-view bars and fine dining. Some participating restaurants in tourist hotspots will even stay open until midnight or into the early hours of the morning, allowing locals and visitors to easily experience Hong Kong&#039;s late-night dining culture, which only gets better as the night goes on.</div><div><br></div><div>Theme 4: Cocktail Fest Month</div><div><br></div><div>"Cocktail Fest Month" handpicked 30 distinctive bars across the city and recommends six themed bar routes, covering hidden speakeasies, local Hong Kong flavours, classic bars in Central, trendy rising mixology stars, luxury hotel and renowned bars, and tipsy pairings of food and drinks. Locals and visitors are invited to hop across Hong Kong&#039;s districts to suit their tastes and explore the city&#039;s diverse and vibrant bar culture one glass at a time. During the event, participants simply pay HK$399 to choose one themed route and three participating bars, then redeem a signature drink at each bar as they embark on a themed bar-hopping journey.</div><div><br></div><div>Highlights include Tell Camellia in Central, renowned for its tea-infused cocktails. Its signature cocktail "Iron Tea" draws inspiration from Hong Kong&#039;s long-standing tea culture, bringing local flavours into the glass. Meanwhile, Bar Mind, co-founded by award-winning local mixologists, presents the "Sweet Potatoni", a tribute to the charcoal-roasted chestnuts and roasted sweet potatoes sold on Hong Kong&#039;s streets. Weaving together smoky tea notes and caramel sweetness for a rich local flavour, it underscores the creativity of Hong Kong&#039;s mixology scene.</div><div><br></div><div>Theme 5: Sip and Savour in LKF</div><div><br></div><div>More than 20 restaurants and bars in Lan Kwai Fong will present "Sip and Savour in LKF", a limited-edition night-time experience. Alongside special Gourmet Month food and drinks offers, there will be mixology workshops, retro-themed nights and DJ performances, offering more options for after-dinner gatherings and nights out while showcasing Lan Kwai Fong&#039;s lively and diverse nightlife.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div>   ]]></description>
<pubDate>Mon, 02 Nov 2026 20:55:00 +0700</pubDate>
</item></channel></rss>